

# Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease



Volker H. Haase<sup>1,2,3</sup>

<sup>1</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; <sup>2</sup>Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden; and <sup>3</sup>Department of Molecular Physiology and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

**Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising new class of orally administered drugs currently in late-stage global clinical development for the treatment of anemia of chronic kidney disease (CKD). HIF-PHIs activate the HIF oxygen-sensing pathway and are efficacious in correcting and maintaining hemoglobin levels in patients with non-dialysis- and dialysis-dependent CKD. In addition to promoting erythropoiesis through the increase in endogenous erythropoietin production, HIF-PHIs reduce hepcidin levels and modulate iron metabolism, providing increases in total iron binding capacity and transferrin levels, and potentially reducing the need for i.v. iron supplementation. Furthermore, HIF-activating drugs are predicted to have effects that extend beyond erythropoiesis. This review summarizes clinical data from current HIF-PHI trials in patients with anemia of CKD, discusses mechanisms of action and pharmacologic properties of HIF-PHIs, and deliberates over safety concerns and potential impact on anemia management in patients with CKD.**

*Kidney International Supplements* (2021) **11**, 8–25; <https://doi.org/10.1016/j.kisu.2020.12.002>

**KEYWORDS:** anemia; chronic kidney disease; erythropoietin; hepcidin; hypoxia-inducible factor; iron; prolyl hydroxylase domain dioxygenase

Copyright © 2021, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Erythropoiesis-stimulating agents (ESAs) are recombinant versions of human erythropoietin (EPO) and the current mainstay of treatment for anemia of chronic kidney disease (CKD), typically in conjunction with iron supplementation.<sup>1,2</sup> Although ESAs have decreased blood transfusion needs, reduced cardiovascular morbidity and mortality, and improved symptoms associated with severe anemia of CKD with hemoglobin (Hb) target levels of 10 to 11 g/dl,<sup>3–6</sup> higher Hb target levels (i.e.,  $\geq 13$  g/dl) increase the risk for cardiovascular and cerebrovascular events, vascular access thrombosis, progression to end-stage renal disease, and overall mortality.<sup>3,7–9</sup>

The hypoxia-inducible factor (HIF)–prolyl hydroxylase domain (PHD) pathway regulates cellular responses to hypoxia and is involved in multiple diseases, including anemia, polycythemia, ischemic diseases, pulmonary arterial hypertension, and cancer.<sup>10</sup> HIF-PHD inhibitors (HIF-PHIs) are a new class of drugs that activate HIF transcription factors and have broad therapeutic potential in clinical medicine.<sup>11</sup> As anemia therapy, HIF-PHIs promote erythropoiesis primarily through increased endogenous EPO production and modulation of iron metabolism.

HIF-PHIs reversibly inhibit HIF-PHD dioxygenases, which belong to a larger family of enzymes that utilize molecular oxygen and 2-oxoglutarate for hydroxylation.<sup>12</sup> HIF-PHIs are currently in advanced global clinical development for anemia management in patients with CKD. Four compounds are approved for marketing in Japan: daprodustat (Duvroq, Kyowa Kirin Co., Ltd.),<sup>13–15</sup> roxadustat (Evrenzo, Astellas Pharma; for dialysis-dependent CKD),<sup>16–18</sup> vadadustat (Vafseo, Akebia Therapeutics),<sup>19,20</sup> and enarodustat (Enaroy, Japan Tobacco Inc.).<sup>21</sup> Roxadustat is also approved for marketing in China.<sup>22,23</sup> Licensing of HIF-PHIs is expected soon in North America and Europe.


This review discusses the mechanisms of action and pharmacologic properties of HIF-PHIs, summarizes clinical data from HIF-PHI trials in patients with anemia of CKD, and considers their clinical efficacy, safety, and potential advantages compared with the current standard of care.

## DISCOVERY OF HIF AND MECHANISM OF ACTION

A classic response to hypoxia is the increase in red blood cell mass. This response is mediated by the glycoprotein hormone EPO, which was purified from the urine of patients with aplastic anemia in 1977<sup>24</sup>; the EPO gene was cloned in

**Correspondence:** Volker H. Haase, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, C-3119A MCN, 1161 21st Ave S, Nashville, Tennessee 37232-2372, USA. E-mail: [volker.haase@vanderbilt.edu](mailto:volker.haase@vanderbilt.edu)

Received 2 October 2020; revised 18 December 2020; accepted 29 December 2020




**Figure 1 | Schematic diagram of the hypoxia-inducible factor (HIF) pathway.** HIF- $\alpha$  is constitutively produced and rapidly degraded under normoxic conditions. Degradation of HIF- $\alpha$  is mediated by prolyl hydroxylase domain (PHD) 1, PHD2, and PHD3 enzymes, which hydroxylate specific proline residues within HIF- $\alpha$ . Hydroxylated HIF- $\alpha$  is ubiquitylated by the von Hippel–Lindau (VHL)–E3 ubiquitin ligase complex, leading to its proteasomal degradation. PHDs utilize  $O_2$  and 2-oxoglutarate as substrates in an iron-dependent reaction, resulting in the formation of hydroxylated HIF- $\alpha$ , succinate, and  $CO_2$ . Hypoxia or HIF–PHD inhibitors (PHIs) reduce PHD catalytic activity, which leads to cellular accumulation of HIF- $\alpha$ , its nuclear translocation, heterodimerization with HIF- $\beta$ , and increased transcription of HIF-regulated genes, which are involved in multiple biological processes. Factor-inhibiting HIF (FIH) modulates HIF transcriptional activity via hydroxylation of a C-terminal asparagine residue within HIF- $\alpha$ . *EPO*, erythropoietin; *LDH*, lactate dehydrogenase; *PGK1*, phosphoglycerate kinase 1; *VEGF*, vascular endothelial growth factor.

1985.<sup>25,26</sup> The molecular mechanisms that regulate the hypoxic induction of EPO, however, were not understood until the discovery that human hepatoma cells were capable of producing EPO under hypoxic conditions.<sup>27</sup> This discovery facilitated the identification and characterization of a regulatory DNA sequence located within the 3' enhancer region of the *EPO* gene,<sup>28</sup> which was shown to bind a nuclear factor under hypoxia, named HIF-1.<sup>29</sup> HIF-1 was subsequently purified from large-scale HeLa and Hep3B cell cultures, sequenced, and found to consist of 2 protein subunits, HIF-1 $\alpha$  and HIF-1 $\beta$  (described below).<sup>30,31</sup> Further studies demonstrated that in addition to the hypoxic induction of EPO in the kidney and liver, HIF-1 played a more general role, regulating hypoxia-sensitive genes, including those encoding glycolytic enzymes (e.g., phosphoglycerate kinase 1 and lactate dehydrogenase A) and angiogenic factors, such as vascular endothelial growth factor (VEGF).<sup>32–35</sup> Subsequently, HIF transcriptional activity was found to be controlled by hydroxylation of specific proline residues within the oxygen-regulated HIF-1 $\alpha$  subunit, leading to its ubiquitylation and proteasomal degradation.<sup>36–38</sup> HIF- $\alpha$  hydroxylation is mediated by a family of prolyl-4-hydroxylases, PHD enzymes, which function as the primary oxygen sensors of the HIF pathway.<sup>39–42</sup> In 2019, the Nobel Prize in Physiology or Medicine was awarded to

Professor William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza for their contributions to delineating the molecular mechanisms underlying HIF oxygen sensing.<sup>43</sup>

The HIF/PHD oxygen-sensing pathway plays a central role in cellular adaptation to hypoxia, regulating biologic processes essential for cell survival. These include glycolysis, mitochondrial metabolism, angiogenesis, immune responses, and erythropoiesis (Figure 1).<sup>10</sup> HIF transcription factors, of which HIF-1 and HIF-2 are extensively studied, belong to a larger family of proteins that regulate responses to environmental stresses and are composed of 2 subunits: an oxygen-sensitive  $\alpha$ -subunit (HIF-1 $\alpha$ , HIF-2 $\alpha$ , or HIF-3 $\alpha$ ) and a constitutively expressed  $\beta$ -subunit.<sup>44</sup> HIF-1 $\alpha$  and HIF-2 $\alpha$  heterodimerize with HIF- $\beta$  to form HIF-1 and HIF-2 transcription factors, respectively.

During normoxia, continuously synthesized HIF- $\alpha$  subunits are hydroxylated by PHD enzymes, of which there are 3 isoforms (PHD1, PHD2, and PHD3).<sup>39–42</sup> PHD enzymes are dioxygenases that utilize molecular oxygen and 2-oxoglutarate as substrates for HIF- $\alpha$  hydroxylation in an iron-dependent manner. This reaction initiates degradation of HIF- $\alpha$  via von Hippel–Lindau–mediated ubiquitylation and prevents the formation of HIF transcription factors.<sup>45</sup> In contrast, hypoxia and pharmacologic HIF-PHD inhibition impairs HIF- $\alpha$



**Figure 2 | Overview of hypoxia-inducible factor (HIF) regulation of erythropoiesis.** Reprinted from *Advances in Chronic Kidney Disease*, volume 26, issue 4, Sanghani NS, Haase VH, Hypoxia-inducible factor activators in renal anemia: current clinical experience, pages 253–266, Copyright © 2019, with permission from the National Kidney Foundation, Inc.<sup>51</sup> In response to hypoxia or HIF- prolyl-hydroxylase inhibitors (PHIs), HIF-2 stimulates erythropoietin (EPO) production in the kidneys and liver. This promotes erythropoiesis and leads to increased iron demand in the bone marrow. HIF coordinates erythropoiesis with iron metabolism, as it regulates genes involved in iron uptake, release from internal stores, and transport (highlighted in red). Absorbed and stored iron is released into the circulation via ferroportin (FPN) and complexed with transferrin (TF) for transport to liver, bone marrow, reticulocyte endothelial system (RES), and other organs. FPN surface expression is regulated by hepcidin, whereas HIF-2 participates in the transcriptional regulation of FPN. Erythroferrone (ERFE) mediates suppression of hepcidin production in the liver under conditions of accelerated erythropoiesis. Ceruloplasmin (CP) is an HIF-regulated copper-carrying ferroxidase that catalyzes the oxidation of ferrous ( $\text{Fe}^{2+}$ ) to ferric ( $\text{Fe}^{3+}$ ) iron. DCYTB, duodenal cytochrome B (cytochrome b reductase 1); DMT1, divalent metal transporter 1; Hb, hemoglobin.

degradation, increasing intracellular HIF- $\alpha$  levels and resulting in the formation of transcriptionally active HIF heterodimers.<sup>45</sup> An independent second hypoxic switch operates at the C-terminal end of HIF- $\alpha$ , with the hydroxylation of an asparagine residue by factor-inhibiting HIF. This asparagine modification modulates the recruitment of coactivators to the HIF transcriptional complex.<sup>46,47</sup>

### HIF IN ERYTHROPOIESIS

Although HIF-1 was first identified as the transcription factor that regulates EPO in human hepatoma cells, *in vivo* hypoxic stimulation of EPO and erythropoiesis is primarily mediated by HIF-2.<sup>48–50</sup> Its  $\alpha$ -subunit was initially described as vascular HIF-1 $\alpha$ -like factor (referred to as endothelial PAS domain protein-1),<sup>44</sup> but it was soon realized that HIF-2 $\alpha$  was not restricted to endothelial cells. HIF-2 induces hepatic and renal EPO expression and promotes the transcription of several iron metabolism and transport genes, including duodenal cytochrome b (*DCYTB*), divalent metal transporter 1 (*DMT1*), and ferroportin (*FPN1*) (Figure 2).<sup>50,51</sup> HIF-1 and HIF-2 have been shown to regulate transferrin (*TF*), TF receptor 1, and ceruloplasmin (*CP*).<sup>48,49,52</sup> Therefore, pharmacologic HIF activation is predicted to enhance enteral iron uptake and transport through increased expression of iron metabolism and transport genes. Indeed, increased *DCYTB* and *DMT1* expression was observed after administration of an HIF-activating compound in normal and inflamed rodents.<sup>53</sup>

A key regulator of iron metabolism is hepcidin, a small hepatic peptide that facilitates degradation of the cell surface iron exporter ferroportin and controls iron availability for erythropoiesis.<sup>54</sup> Hepcidin plays a central role in the pathogenesis of anemia of inflammation and is elevated in patients with CKD due to reduced renal clearance and the presence of uremic inflammation.<sup>55–57</sup> Elevated serum hepcidin levels in CKD are associated with atherosclerosis, cardiovascular disease, and increased mortality.<sup>57</sup>

Increased serum hepcidin impairs the release of iron from internal stores and reduces intestinal iron uptake, whereas low serum hepcidin has the inverse effect.<sup>58</sup> Hepcidin synthesis is suppressed when iron stores are low or when iron demands increase as a result of accelerated erythropoiesis (e.g., under hypoxic or anemic conditions or following ESA administration).<sup>59–62</sup> Conversely, hepcidin production increases in response to iron loading or increased systemic iron. Serum hepcidin levels also increase with inflammation, mediated by inflammatory cytokine signaling in hepatocytes.<sup>59</sup> Erythropoietic drive during ineffective erythropoiesis generates an overriding signal that results in the suppression of hepcidin transcription, even with excessive systemic iron.<sup>63</sup>

Erythroferrone, which is produced by bone marrow erythroid progenitor cells, is the main mediator of hepcidin suppression during increased erythropoietic activity.<sup>63</sup> This appears to involve blockade of bone morphogenetic protein signaling pathways that normally increase hepcidin transcription.<sup>64</sup> Similar to ESA administration, stimulation of

**Table 1 | Summary of the pharmacologic properties of hypoxia-inducible factor–prolyl hydroxylase inhibitors**

| Variable                              | Daprodustat <sup>68,69</sup><br>(GSK1278863) | Desidustat <sup>70</sup><br>(ZYAN1) | Enarodustat <sup>71,72</sup><br>(JTZ-951) | Molidustat <sup>68,73,74</sup><br>(BAY 85-3934) | Roxadustat <sup>68,75</sup><br>(FG-4592; ASP1517;<br>AZD9941) | Vadadustat <sup>68,76</sup><br>(AKB-6548;<br>MT-6548) |  |
|---------------------------------------|--|-------------------------------------|---|---|---|---|--|
| <b>Pharmacodynamics</b>               |  |                                     |   |   |   |   |  |
| IC <sub>50</sub> , μmol/L             |  |                                     |   |   |   |   |  |
| MALDI-TOF binding assay               | PHD1: 1.50<br>PHD2: 2.87<br>PHD3: 0.61       |                                     |   |   | PHD1: 1.40<br>PHD2: 1.85<br>PHD3: 0.72                        | PHD1: 1.40<br>PHD2: 1.26<br>PHD3: 1.32                | PHD1: 0.84<br>PHD2: 2.30<br>PHD3: 0.26 |
| <i>In vitro</i> assay in HepG2 cells  |  | 11.2 <sup>a</sup>                   |   |   |   |   |  |
| Fluorescent enzyme assay              |  |                                     |   | PHD1: 0.016<br>PHD2: 0.061<br>PHD3: 0.101       |   |   |  |
| <b>Pharmacokinetics</b>               |  |                                     |   |   |   |   |  |
| Participants                          | Japan, n = 13 <sup>b</sup>                   | Cauc, n = 12 <sup>b</sup>           | Cauc, n = 56 <sup>b</sup>                 | Mixed, <sup>c</sup> n = 6 <sup>d</sup>          | Japan, n = 9 <sup>b</sup>                                     | Japan, n = 15 <sup>b</sup>                            | Cauc, n = 8 <sup>b</sup>               |
| Dose, mg                              | 100  | 100                                 | 10–300                                    | 10  | 50  | 100   | 450                                    |
| AUC, μg·h/ml <sup>e</sup>             | 5.20 <sup>f</sup>                            | 3.55 <sup>f</sup>                   | 3.7–116.2                                 | 7.33 <sup>f</sup>                               | 1.11  | 88.7 <sup>f</sup>                                     | 397 <sup>f</sup>                       |
| C <sub>max</sub> , μg/ml <sup>e</sup> | 2.32   | 1.60                                | 0.6–17.9                                  | 0.986   | 0.56  | 10.6  | 52.6                                   |
| T <sub>max</sub> , h <sup>g</sup>     | 1.50   | 1.50                                | 1.25–3.00                                 | 0.5   | 0.75  | 2.0   | 2.0                                    |
| t <sub>1/2</sub> , h <sup>e</sup>     | 2.25   | 1.86                                | 7.0–11.4                                  | 25.9 <sup>h</sup> ; 8.96 <sup>i</sup>           | 10.4  | 13.1  | 5.8 <sup>j</sup>                       |
| CL/F, L/h <sup>e</sup>                | 21.70  | 31.4                                | 2.1–2.9                                   | 1.52  | 45.1  | 1.18  | NR                                     |
| CL <sub>R</sub> , L/h <sup>e</sup>    | NR   | NR                                  | NR  | NR  | 0.693   | 0.0261  | NR                                     |
| Metabolizing enzymes                  | CYP2C8, major<br>CYP3A4, minor               |                                     | NR  | CYP2C8,<br>CYP2C9, CYP3A4                       | UGTs  | CYP2C8, major   | UGT1A9, major                          |

AUC, area under the concentration-time curve; Cauc, Caucasian; CL/F, apparent oral clearance; CL<sub>R</sub>, renal clearance; C<sub>max</sub>, peak plasma concentration; CYP, cytochrome P450; IC<sub>50</sub>, 50% PHD inhibitory concentration; Japan, Japanese; MALDI-TOF, matrix-assisted laser desorption ionization–time of flight; NR, not reported; PHD, prolyl hydroxylase domain; t<sub>1/2</sub>, elimination half-life; T<sub>max</sub>, time to C<sub>max</sub>; UGT, uridine 5'-diphospho-glucuronosyltransferase.

<sup>a</sup>PHD enzyme isoform not specified.

<sup>b</sup>Single-dose oral administration in fasted, healthy volunteers.

<sup>c</sup>Participants were either Caucasian (n = 1), Black (n = 4), or American Indian/Alaskan Native (n = 1).

<sup>d</sup>Single-dose oral administration in patients with end-stage renal disease on maintenance hemodialysis.

<sup>e</sup>Mean.

<sup>f</sup>Reported as AUC from time 0 to infinity.

<sup>g</sup>Median.

<sup>h</sup>Terminal t<sub>1/2</sub>.

<sup>i</sup>Effective t<sub>1/2</sub>.

<sup>j</sup>Value of 7.8 in patients with hepatic impairment.

erythropoiesis with HIF-PHIs lowers serum hepcidin levels.<sup>51</sup> Cell culture– and animal-based studies have established that both liver-specific and systemic HIF activation suppress hepcidin transcription in an EPO-dependent manner that requires erythropoiesis.<sup>65–67</sup> However, HIF-PHI effects that are independent of erythropoiesis cannot be completely excluded.

**PHARMACOLOGY OF HIF-PHIS**

HIF-PHIs in current clinical development are potent reversible inhibitors of all 3 PHD isoforms, with *in vitro* half-maximal inhibitory concentrations in the submicromolar to low micromolar range (Table 1<sup>68–76</sup>).<sup>68,70,71</sup> HIF-PHIs chelate at the catalytic-site iron, stabilizing both HIF-1α and HIF-2α and resulting in dose-dependent increases in HIF-regulated gene expression.<sup>68</sup> However, differences between daprodustat, molidustat, roxadustat, and vadadustat were found in the

kinetics of HIF-α stabilization and relative expression levels of HIF-regulated genes in cells exposed to equimolar amounts of compound.<sup>68</sup> Significant activity against factor-inhibiting HIF and other 2-oxoglutarate–dependent dioxygenases was not detected.<sup>68</sup> Because of differences in pharmacokinetics, the effective dosing schedules for HIF-PHIs vary, with roxadustat being administered 3 times weekly, compared with once-daily administration for daprodustat, enarodustat, molidustat, and vadadustat.<sup>51,77,78</sup> Based on phase 1 and 2 data, higher once-daily doses of daprodustat and molidustat may be required in patients on dialysis to achieve target Hb levels.<sup>79,80</sup>

**Pharmacokinetic profiles**

The pharmacokinetic parameters for single-dose HIF-PHIs, which are rapidly absorbed after oral administration, are summarized in Table 1.<sup>69–73,75,76</sup> Roxadustat and daprodustat are primarily oxidized by cytochrome P450 (CYP) 2C8, with a

**Table 2 | Summary of clinical efficacy data from phase 3 clinical trials of hypoxia-inducible factor–prolyl hydroxylase inhibitors in patients with anemia and non-dialysis-dependent chronic kidney disease**

| Study   | Study design; no. of patients                 | Treatment, duration  | Hb response rate <sup>a</sup>  | Mean ΔHb from baseline  |
|---|---|--|--|---|
| <b>Daprodustat</b><br>Kimura <i>et al.</i> , 2019 <sup>15</sup> (NCT02791763) | R, OL, AC; ESA-naïve and ESA-treated; n = 299 | DAPRO QD <sup>b</sup> vs. CERA, 52 wk                              | Hb at target (11–13 g/dl) during weeks 40–52:<br>DAPRO: 92%<br>CERA: 92%   | Difference in mean Hb (weeks 40–52):<br>0.10 (95% CI, –0.07 to 0.28) g/dl       |
| <b>Enarodustat</b><br>Akizawa <i>et al.</i> , 2019 <sup>78</sup>              | R, OL, AC; ESA status NR; n = 216             | ENARO QD <sup>c</sup> vs. DPO, 24 wk                               | Hb at target (10–12 g/dl) during weeks 1–24:<br>ENARO: 89.6%<br>DPO: 90.6%   | Difference in mean Hb (weeks 20–24):<br>0.09 (95% CI, –0.07 to 0.26) g/dl       |
| <b>Molidustat</b><br>MIYABI ND-C <sup>86</sup> (NCT03350321)                  | R, OL, AC; ESA-naïve; n = 161                 | MOLI 25 mg QD <sup>d</sup> vs. DPO, 52 wk                          | NR   | LSM difference in mean Hb (weeks 30–36):<br>–0.38 (95% CI, –0.67 to –0.08) g/dl |
| MIYABI ND-M <sup>87</sup> (NCT03350347)                                       | R, OL, AC; ESA-treated; n = 164               | MOLI QD <sup>e</sup> vs. DPO, 52 wk                                | Hb at target (11–13 g/dl) during weeks 30–36:<br>MOLI: 80.5%<br>DPO: NR  | LSM difference in mean Hb (weeks 30–36):<br>0.13 (95% CI, –0.15 to 0.40) g/dl   |
| <b>Roxadustat</b><br>Chen <i>et al.</i> , 2019 <sup>23</sup> (NCT02652819)    | R, DB, PC; ESA-naïve; n = 152                 | ROXA 70 or 100 mg TIW <sup>f</sup> vs. PBO, 8 wk DB, then 18 wk OL | At week 9:<br>ROXA: 84%<br>PBO: 0%   | During weeks 7–9:<br>ROXA: 1.9 g/dl<br>PBO: –0.4 g/dl ( <i>P</i> < 0.001)       |
| Akizawa <i>et al.</i> , 2020 <sup>88</sup> (NCT02964936)                      | R, OL, NC; ESA-naïve; n = 99                  | ROXA 50 or 70 mg TIW <sup>c</sup> , 24 wk                          | From baseline to EOT:<br>Hb at target ≥10 g/dl:<br>ROXA (50 mg): 97.0%<br>ROXA (70 mg): 100.0%<br>Hb at target ≥10.5 g/dl:<br>ROXA (50 mg): 94.9%<br>ROXA (70 mg): 98.0% | During weeks 18–24:<br>ROXA (50 mg): 1.34 g/dl<br>ROXA (70 mg): 1.30 g/dl       |
| Akizawa <i>et al.</i> , 2020 <sup>89</sup>                                    | R, OL, AC; ESA-treated; n = 262               | ROXA vs. DPO, 52 wk  | Mean Hb during weeks 18–24:<br>ROXA: 11.14 g/dl  | Difference in mean Hb (weeks 18–24):<br>–0.07 g/dl                              |
| ALPS <sup>90</sup> (NCT01887600)  | R, DB, PC; ESA-naïve; n = 594                 | ROXA vs. PBO, 52–104 wk  | NR   | During weeks 28–52:<br>ROXA: 1.99 g/dl<br>PBO: 0.41 g/dl ( <i>P</i> < 0.001)    |
| ANDES <sup>91</sup> (NCT01750190)   | R, DB, PC; ESA-naïve; n = 922                 | ROXA TIW <sup>c</sup> vs. PBO, 52 wk                               | During weeks 1–24:<br>ROXA: 86.0%<br>PBO: 6.6% ( <i>P</i> = 0.0007)  | During weeks 28–52:<br>ROXA: 2.00 g/dl<br>PBO: 0.16 g/dl ( <i>P</i> < 0.0001)   |
| OLYMPUS <sup>92</sup> (NCT02174627)   | R, DB, PC; ESA-naïve; n = 2781                | ROXA 70 mg TIW <sup>g</sup> vs. PBO, 52 wk                         | During weeks 1–24:<br>ROXA: 77.0%<br>PBO: 8.5% ( <i>P</i> < 0.001)   | During weeks 28–52:<br>ROXA: 1.75 g/dl<br>PBO: 0.40 g/dl ( <i>P</i> < 0.001)    |
| DOLOMITES <sup>93</sup> (NCT02021318)   | R, OL, AC; ESA-naïve; n = 616                 | ROXA TIW vs. DPO, 104 wk   | During weeks 1–24 <sup>h</sup> :<br>ROXA: 89.5%<br>DPO: 78.0%  | NR  |

**Table 2 |** (Continued)

| Study   | Study design; no. of patients                 | Treatment, duration  | Hb response rate <sup>a</sup> | Mean ΔHb from baseline  |
|---|---|--|-------------------------------|---|
| <b>Vadadustat</b><br>Nangaku et al., 2019 <sup>19</sup> (NCT03329196) | R, OL, AC; ESA-naïve and ESA-treated; n = 304 | VADA 300 mg QD, then 150–600 mg QD <sup>d</sup> vs. DPO, 52 wk | NR                            | LSM of average Hb (weeks 20 and 24):<br>VADA: 11.66 g/dl<br>DPO: 11.93 g/dl     |
| PRO2TECT <sup>94</sup> (NCT02648347)                                  | R, OL, AC; ESA-naïve; n = 1751                | VADA QD vs. DPO, 52 wk   | NR                            | Difference (VADA vs. DPO):<br>weeks 24–36: 0.05 g/dl<br>weeks 40–52: 0.04 g/dl  |
| PRO2TECT <sup>94</sup> (NCT02680574)                                  | R, OL, AC; ESA-treated; n = 1725              | VADA QD vs. DPO, 52 wk   | NR                            | Difference (VADA vs. DPO):<br>weeks 24–36: –0.01 g/dl<br>weeks 40–52: 0.00 g/dl |

AC, active controlled; CERA, continuous erythropoietin receptor activator (epoetin beta pegol); CI, confidence interval; DAPRO, daprodustat; DB, double blind; DPO, darbepoetin alfa; ENARO, enarodustat; EOT, end of treatment; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; LSM, least-squares mean; MOLI, molidustat; NC, noncomparative; NR, not reported; OL, open label; PBO, placebo; PC, PBO controlled; QD, once daily; R, randomized; ROXA, roxadustat; TIW, 3 times weekly; VADA, vadadustat.  
<sup>a</sup>ESNA-naïve is defined as no use of ESA for a study-defined time period before start of study.  
<sup>b</sup>Defined as the proportion of patients with an increase in Hb from baseline of  $\geq 1$  g/dl, unless defined otherwise.  
<sup>c</sup>Started at 2 and 4 mg QD in ESA-naïve patients with baseline Hb 9 to  $<11$  and 8 to  $<9$  g/dl, respectively, and 4 mg QD in ESA-treated patients with baseline Hb 9 to 13 g/dl; dose adjusted to maintain Hb levels of 11 to 12 g/dl.  
<sup>d</sup>Dose adjusted to achieve and maintain Hb levels of 10 to 12 g/dl.  
<sup>e</sup>Dose adjusted to achieve and maintain Hb levels of 11 to 13 g/dl.  
<sup>f</sup>Starting dose based on prior ESA dose; dose adjusted to achieve and maintain Hb levels of 11 to 13 g/dl.  
<sup>g</sup>Weight-based dosing ( $>40$ –60 or  $\geq 60$  kg), adjusted every 4 weeks to maintain Hb levels of 10 to 12 g/dl.  
<sup>h</sup>Tiered, weight-based dosing.  
<sup>i</sup>Hb response defined as Hb  $\geq 11$  g/dl and an increase in Hb from baseline of  $\geq 1$  g/dl in patients with baseline Hb  $>8$  g/dl or  $\geq 2$  g/dl in patients with baseline Hb  $\leq 8$  g/dl.

minor contribution of CYP3A4 to daprodustat metabolism.<sup>81,82</sup> In addition to CYP2C8-mediated oxidation, roxadustat undergoes phase 2 hydrophilic modification by glucuronidation and glucosidation.<sup>75,83</sup> Enarodustat is also metabolized by CYP enzymes,<sup>72</sup> whereas molidustat and vadadustat are primarily metabolized by uridine 5'-diphospho-glucuronosyltransferases.<sup>74,76</sup>

Changes in renal function are unlikely to affect elimination rates of nonmodified daprodustat and roxadustat as their renal clearance is low (Table 1).<sup>73,75</sup> Where reported, coadministration with meals did not substantially affect the pharmacokinetics of roxadustat and daprodustat,<sup>75,81</sup> nor did the coadministration of the phosphate binder lanthanum carbonate<sup>75</sup> or the proton-pump inhibitor omeprazole<sup>84</sup> affect roxadustat pharmacokinetics.

**Potential drug-drug interactions**

Because of the high prevalence of comorbidities and concomitant medication use in CKD patients, HIF-PHIs should be carefully screened for potential drug-drug interactions. Given that HIF-PHIs are metabolized by CYP enzymes, studies have assessed potential interactions between roxadustat or daprodustat and other CYP substrates or inhibitors, such as warfarin and gemfibrozil. These studies suggest that warfarin does not require dose adjustment when coadministered with roxadustat,<sup>84</sup> whereas gemfibrozil, a strong irreversible CYP2C8 inhibitor, significantly increased daprodustat plasma levels and reduced its rate of elimination.<sup>79</sup> Data with gemfibrozil and roxadustat have not been published. Daprodustat exposure was also mildly increased (~1.5 fold) by trimethoprim (a weak CYP2C8 inhibitor).<sup>85</sup> The pharmacokinetics of pioglitazone, a CYP2C8 substrate, and rosuvastatin, a substrate of organic anion transporter P1B1 (which is inhibited by daprodustat), were not affected by daprodustat coadministration.<sup>85</sup>

**HIF-PHIs IN CLINICAL TRIALS**

HIF-PHIs stimulate erythropoiesis in a dose-dependent manner and have consistently shown clinical efficacy in patients with anemia of non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD in phase 2 and 3 studies. Data from completed phase 3 trials are discussed herein and summarized in Tables 2<sup>86–94</sup> and 3.<sup>95–99</sup> Currently ongoing phase 3 studies evaluating efficacy and major adverse cardiovascular event (MACE) end points are summarized in Table 4.

**Non-dialysis-dependent CKD**

Dose-dependent increases in Hb levels were observed in phase 2 studies of orally administered daprodustat,<sup>100–102</sup> desidustat,<sup>103</sup> enarodustat,<sup>104</sup> molidustat,<sup>80,105</sup> roxadustat,<sup>106–109</sup> and vadadustat<sup>110–112</sup> over 4- to 30-week treatment periods in recombinant human EPO-naïve patients or patients with prior exposure to ESA. Of the HIF-PHIs in development, phase 3 data in NDD CKD patients are reported for daprodustat,<sup>15</sup> enarodustat,<sup>78</sup> molidustat,<sup>86,87</sup> roxadustat,<sup>23,88–93</sup> and vadadustat<sup>19,94</sup> (Table 2). Roxadustat,

**Table 3 | Summary of clinical efficacy data from phase 3 clinical trials of hypoxia-inducible factor–prolyl hydroxylase inhibitors in patients with anemia and dialysis-dependent chronic kidney disease**

| Study  | Study design; no. of patients   | Treatment, duration   | Hb response rate <sup>a</sup>  | Mean ΔHb from baseline   |
|--|---|---|--|--|
| <b>Daprodustat</b>   |   |   |  |  |
| Tsubakihara <i>et al.</i> , 2019 <sup>13</sup><br>(NCT02829320)          | OL, NC; ESA-naïve, I-HD and M-HD; n = 28                                      | DAPRO 4 mg QD <sup>b</sup> , 24 wk  | During weeks 1–4: 39%  | After 4 weeks: 0.79 g/dl   |
| Akizawa <i>et al.</i> , 2020 <sup>14</sup><br>(NCT02969655)              | R, DB, AC; ESA-treated, M-HD; n = 271   | DAPRO 4 mg QD <sup>b</sup> vs. DPO, 52 wk   | Hb within target range (10–12 g/dl) during weeks 40–52: DAPRO: 88% DPO: 90%                    | During weeks 40–52: DAPRO: 0.0 g/dl DPO: 0.0 g/dl Adjusted difference vs. DPO: 0.1 (95% CI, –0.1 to 0.2) g/dl          |
| <b>Enarodustat</b>   |   |   |  |  |
| Akizawa <i>et al.</i> , 2019 <sup>77</sup>                               | R, DB, AC; ESA-treated, M-HD; n = 173   | ENARO QD <sup>c</sup> vs. DPO; 24 wk  | Hb within target range (10–12 g/dl) during weeks 1–24: ENARO: 78.2% DPO: 88.8%                 | Difference in mean Hb (weeks 20–24): –0.12 (–0.33 to 0.10) g/dl  |
| <b>Molidustat</b>  |   |   |  |  |
| MIYABI HD-M <sup>95</sup><br>(NCT03543657)                               | R, DB, AC; ESA-treated, M-HD; n = 229   | MOLI 5–200 mg QD <sup>b</sup> vs. DPO; 52 wk  | NR   | LSM difference in Hb change from baseline (weeks 33–36): –0.13 g/dl  |
| <b>Roxadustat</b>  |   |   |  |  |
| Chen <i>et al.</i> , 2019 <sup>22</sup><br>(NCT02652806)                 | R, OL, AC; ESA-treated, M-DD; n = 304   | ROXA 100 or 120 mg TIW <sup>d</sup> vs. Epoetin alfa, 26 wk   | During weeks 23–27: ROXA: 92.5% Epoetin alfa: 92.5%  | During weeks 23–27: ROXA: 0.7 g/dl Epoetin alfa: 0.5 g/dl Difference vs. Epoetin alfa: 0.2 (95% CI, –0.02 to 0.5) g/dl |
| Akizawa <i>et al.</i> , 2020 <sup>16</sup><br>(NCT02779764, NCT02780141) | R, OL, NC; ESA-naïve (I-HD) and ESA-treated (M-HD); n = 239                   | ESA-naïve: ROXA 50 or 70 mg TIW <sup>d</sup> , 24 wk<br>ESA-treated: ROXA 70 or 100 mg TIW <sup>e</sup> , 52 wk | From baseline to EOT <sup>f</sup> :<br>ESA-naïve: 87.8%<br>ESA-treated: NR                     | During weeks 18–24: ESA-naïve: 2.26 g/dl<br>ESA-treated: –0.03 g/dl<br>During weeks 46–52: ESA-treated: 0.12 g/dl      |
| Akizawa <i>et al.</i> , 2020 <sup>17</sup><br>(NCT02780726)              | R, OL, NC; ESA-naïve and ESA-treated, PD (>4 wk); n = 56                      | ROXA 50 or 70 mg TIW (ESA-naïve) or ROXA 70 or 100 mg (ESA-treated), 24 wk                                      | Hb within target range (10–12 g/dl) during weeks 18–24: ESA-naïve: 92.3%<br>ESA-treated: 74.4% | During weeks 18–24: ESA-naïve: 1.69 g/dl<br>ESA-treated: 0.14 g/dl   |
| Akizawa <i>et al.</i> , 2020 <sup>18</sup><br>(NCT02952092)              | R, DB, AC; ESA-treated, M-HD; n = 303   | ROXA 70 or 100 mg TIW vs. DPO QW, 24 wk   | Hb within target range (10–12 g/dl) during weeks 18–24: ROXA: 95.2%<br>DPO: 91.3%              | During weeks 18–24: ROXA: –0.04 g/dl<br>DPO: –0.03 g/dl<br>Difference vs. DPO: –0.02 (95% CI, –0.18 to 0.15) g/dl      |
| HIMALAYAS <sup>96</sup><br>(NCT02052310)                                 | R, OL, AC, ESA-naïve and ESA-limited use, I-DD; n = 1043                      | ROXA TIW vs. Epoetin alfa, 52 wk  | During weeks 1–24: ROXA: 88.2%<br>Epoetin alfa: 84.4%  | During weeks 28–52: ROXA: 2.57 g/dl<br>Epoetin alfa: 2.36 g/dl ( <i>P</i> < 0.001 vs. Epoetin alfa)                    |
| PYRENEES <sup>90</sup><br>(NCT02278341)                                  | R, OL, AC, ESA-treated, M-DD; n = 836   | ROXA 100, 150, or 200 mg TIW <sup>e</sup> vs. ESA, 52–104 wk  | NR   | During weeks 28–52: ROXA: 0.40 g/dl<br>ESA: 0.18 g/dl ( <i>P</i> < 0.001 vs. ESA)                                      |
| ROCKIES <sup>97</sup><br>(NCT02174731)                                   | R, OL, AC; ESA-naïve and ESA-treated, M-DD and I-DD (n = 416); total n = 2133 | ROXA TIW <sup>g</sup> vs. Epoetin alfa, 52 wk   | Proportion of time with Hb ≥10 g/dl during weeks 28–52: ROXA: 79%<br>Epoetin alfa: 76%         | During weeks 28–52: ROXA: 0.77 g/dl<br>Epoetin alfa: 0.68 g/dl ( <i>P</i> < 0.05 vs. Epoetin alfa)                     |
| SIERRAS <sup>98</sup><br>(NCT02273726)                                   | R, OL, AC; ESA-treated, M-DD and I-DD (n = 371); total n = 741                | ROXA TIW <sup>h</sup> vs. Epoetin alfa, 52 wk   | NR   | During weeks 28–52: ROXA: 0.39 g/dl<br>Epoetin alfa: –0.09 g/dl ( <i>P</i> < 0.0001 vs. Epoetin alfa)                  |

(Continued on following page)

**Table 3 |** (Continued)

| Study  | Study design; no. of patients                              | Treatment, duration   | Hb response rate <sup>a</sup>   | Mean ΔHb from baseline   |
|--|--|---|---|--|
| <b>Vadadustat</b><br>Nangaku <i>et al.</i> , 2019 <sup>20</sup><br>(NCT03439137) | R, DB, AC; ESA-treated, M-HD;<br>n = 323                   | VADA 300 mg QD, then<br>150–600 mg <sup>b</sup> vs. DPO,<br>52 wk | Hb within target range<br>(10–12 g/dl) at week 24:<br>VADA: 75.4%<br>DPO: 75.7% | LSM of average Hb (weeks 20<br>and 24):<br>VADA: 10.61 g/dl<br>DPO: 10.65 g/dl                   |
| INNO2VATE <sup>99</sup><br>(NCT02865850)   | R, DB, AC; ESA-naïve<br>and ESA-treated; I-DD;<br>n = 369  | VADA vs. DPO, 52 wk   | NR  | LSM difference in Hb change:<br>During weeks 24–36: –0.3 g/dl<br>During weeks 40–52: –0.07 g/dl  |
| INNO2VATE <sup>99</sup><br>(NCT02892149)   | R, DB, AC; ESA-naïve<br>and ESA-treated; M-DD;<br>n = 3554 | VADA vs. DPO, 52 wk   | NR  | LSM difference in Hb change:<br>During weeks 24–36: –0.17 g/dl<br>During weeks 40–52: –0.18 g/dl |

AC, active controlled; CI, confidence interval; DAPRO, daprodustat; DB, double blind; DPO, darbepoetin alfa; ENARO, enarodustat; EOT, end of treatment; ESA, erythropoietin-stimulating agent; Hb, hemoglobin; I-DD, incident dialysis (hemodialysis and PD); I-HD, incident hemodialysis; LSM, least-squares mean; M-DD, maintenance/stable dialysis (hemodialysis and PD); M-HD, maintenance/stable hemodialysis; MOLI, molidustat; NC, noncomparative; NR, not reported; OL, open label; PD, peritoneal dialysis; QD, once daily; QW, once weekly; R, randomized; ROXA, roxadustat; TIW, 3 times weekly; VADA, vadadustat.

<sup>a</sup>Defined as the proportion of patients with an increase in Hb from baseline of  $\geq 1.0$  g/dl, unless defined otherwise.

<sup>b</sup>Titrated to maintain Hb levels of 10 to 12 g/dl.

<sup>c</sup>Weight-based dosing ( $>45$ –60 or  $\geq 60$  kg), adjusted to maintain Hb levels of 10 to 12 g/dl.

<sup>d</sup>Starting dose based on study site, weight, and 2 most recent Hb measurements, adjusted to maintain Hb levels of 10 to 12 g/dl.

<sup>e</sup>Dosed according to average weekly dose of prior ESA therapy, adjusted to maintain Hb levels of 10 to 12 g/dl.

<sup>f</sup>Hb response defined as the proportion of patients with Hb of  $\geq 10$  g/dl and an increase in Hb from baseline of  $\geq 1.0$  g/dl.

<sup>g</sup>Titrated to achieve an Hb level of 11 g/dl and to maintain Hb levels of 10 to 12 g/dl.

<sup>h</sup>Initially dosed according to prior dose of erythropoietin therapy.

orally administered 3 times weekly, effectively corrected Hb levels in a small double-blind, placebo-controlled phase 3 study in China (n = 154; 8-week duration)<sup>23</sup> and in a 2-arm, randomized, open-label, noncomparative study in Japan (n = 99; 24-week duration),<sup>88</sup> and was noninferior to darbepoetin alfa in preliminary results from a 52-week, randomized, open-label, active-comparator study in Japan (n = 262).<sup>89</sup> Preliminary data from the larger international, double-blind, placebo-controlled ALPS (n = 594),<sup>90</sup> ANDES (n = 922),<sup>91</sup> and OLYMPUS (n = 2781)<sup>92</sup> trials indicated that roxadustat was efficacious in correcting and maintaining Hb levels over 52 weeks; and in a preliminary report from the open-label, active-controlled DOLOMITES trial (n = 616), roxadustat was noninferior to darbepoetin alfa in providing Hb response over 24 weeks.<sup>93</sup> Preliminary data from Japanese studies reported that daprodustat was noninferior to epoetin beta pegol (n = 299),<sup>15</sup> whereas enarodustat (n = 216),<sup>78</sup> molidustat (n = 161 and 164),<sup>86,87</sup> and vadadustat (n = 304)<sup>19</sup> were noninferior to darbepoetin alfa for maintaining target Hb levels. In the large global PRO2TECT trial, vadadustat achieved noninferiority compared with darbepoetin alfa in both the correction (n = 1751) and the conversion (n = 1725) arms.<sup>113</sup>

HIF-PHI administration in NDD CKD patients was associated with an increase in total iron binding capacity in most phase 2 and phase 3 studies (mostly placebo controlled).<sup>23,80,88,100,101,103–109,111</sup> Some studies directly measured and reported increases in serum TF,<sup>23,88,102,109</sup> which most likely resulted from HIF-induced stimulation of TF transcription. As predicted, decreases in serum hepcidin and ferritin were reported for all HIF-PHIs,<sup>23,80,88,100,101,103–109,111</sup> which most likely resulted from

increased erythropoietic activity and iron utilization in the bone marrow.<sup>51,114</sup> One study observed relatively greater decreases in serum hepcidin and ferritin with molidustat versus darbepoetin alfa,<sup>105</sup> suggesting that HIF-PHIs may have effects on iron metabolism resulting from distinct, nonerythropoietic mechanisms. Superiority with regard to first i.v. iron use was reported for roxadustat compared with darbepoetin alfa in preliminary results from the DOLOMITES trial.<sup>92</sup> Further investigations that control for iron supplementation and stratify for serum iron markers are needed to corroborate these findings.

### Dialysis-dependent CKD

The clinical efficacy of HIF-PHIs in correcting and maintaining Hb levels in patients with DD CKD has been consistently demonstrated in phase 2 and 3 studies. Phase 2 studies of up to 30 weeks' duration included ESA-converted patients who maintained Hb levels with daprodustat,<sup>100,102,115–117</sup> enarodustat,<sup>118</sup> molidustat,<sup>80</sup> roxadustat,<sup>107,119</sup> or vadadustat,<sup>120</sup> or EPO-naïve incident dialysis patients (dialysis duration, <4 months) who corrected Hb levels with roxadustat.<sup>121</sup> Some phase 2 studies included patients who received placebo for a limited time period of 4 to 6 weeks.<sup>112,115–118</sup>

Clinical efficacy data from phase 3 trials for daprodustat,<sup>13,14</sup> enarodustat,<sup>77</sup> molidustat,<sup>95</sup> roxadustat,<sup>16–18,22,90,96–98</sup> and vadadustat<sup>20,99</sup> are summarized in Table 3. Noninferiority to darbepoetin alfa with regard to maintaining target Hb was reported for daprodustat (n = 271),<sup>14</sup> enarodustat (n = 173),<sup>77</sup> molidustat (n = 229),<sup>95</sup> and vadadustat, in both a study of maintenance hemodialysis patients (n = 323)<sup>20</sup> and the INNO2VATE studies of patients on incident (n = 369) and

**Table 4 | Summary of ongoing NCT-registered clinical studies of hypoxia-inducible factor–prolyl hydroxylase inhibitors in patients with anemia of CKD**

| Study design (identifier)                             | Patients; target no.       | Comparator       | Primary end point(s)   | Completion date |
|---|----------------------------|------------------|--|-----------------|
| <b>Daprodustat</b>                                    |                            |                  |  |                 |
| Phase 2, R, OL, AC, CO (ASCEND: Fe; NCT03457701)      | NDD-CKD; n = 12            | rhEPO            | Fractional iron absorption   | Mar 19, 2021    |
| Phase 2, R, OL, AC, PG (ASCEND-BP; NCT03029247)       | DD-CKD (M-HD); n = 62      | Epoetin alfa     | Mean 6-h postdose SBP at day 57  | Jul 16, 2020    |
| Phase 3, R, DB, PC, PG (ASCEND-NHQ; NCT03409107)      | NDD-CKD; n = 600           | PBO              | Mean change from baseline in Hb at weeks 24–28   | Oct 6, 2020     |
| Phase 3, R, OL, AC, PG (ASCEND-ND; NCT02876835)       | NDD-CKD; n = 4500          | DPO Iron         | 1. Time to the first occurrence of adjudicated MACE<br>2. Mean change from baseline in Hb at weeks 28–52   | Mar 17, 2022    |
| Phase 3, R OL, AC, PG (ASCEND-ID; NCT03029208)        | DD-CKD (I-DD); n = 300     | DPO Iron         | Mean change from baseline in Hb at weeks 28–52   | Oct 8, 2020     |
| Phase 3, R, DB, AC, PG (ASCEND-TD; NCT03400033)       | DD-CKD (M-HD); n = 407     | Epoetin alfa     | Mean change from baseline in Hb at weeks 28–52   | Jun 19, 2020    |
| Phase 3, R, OL, AC, PG (ASCEND-D; NCT02879305)        | DD-CKD (M-DD); n = 2986    | rhEPO            | 1. Time to the first occurrence of adjudicated MACE<br>2. Mean change from baseline in Hb at weeks 28–52   | Nov 25, 2021    |
| <b>Desidustat</b>                                     |                            |                  |  |                 |
| Phase 3, R, OL, AC, PG (DREAM-ND; NCT04012957)        | NDD-CKD; n = 588           | DPO              | Mean change from baseline in Hb at week 24   | Dec 30, 2020    |
| Phase 3, R, OL, AC, PG (DREAM-D; NCT04215120)         | DD-CKD (M-HD); n = 392     | Epoetin alfa     | Mean change from baseline in Hb at week 24   | Nov 30, 2021    |
| <b>Molidustat</b>                                     |                            |                  |  |                 |
| Phase 3, R, DB, DD, AC, PG (MIYABI HD-M; NCT03543657) | DD-CKD (M-HD); n = 220     | DPO              | 1. Mean Hb during weeks 33–36<br>2. Mean change from baseline in Hb at weeks 33–36   | Dec 24, 2019    |
| <b>Roxadustat</b>                                     |                            |                  |  |                 |
| Phase 3, R, OL, AC, PG (NCT02988973)                  | NDD-CKD; n = 334           | DPO              | Change from baseline in mean Hb at weeks 18–24   | Mar 26, 2020    |
| Phase 4, R, OL, AC, PG (NCT04134026)                  | DD-CKD (I-HD); n = 400     | Epoetin alfa     | 1. Mean change in Hb at weeks 28–52<br>2. Hb response rate<br>3. Incidence of CV and cerebrovascular events  | Oct 19, 2023    |
| Phase 4, R, OL, NC, PG (NCT04059913)                  | DD-CKD (HD or PD); n = 306 | None             | Part 1 (weeks 1–20):<br>ESA-naïve: % of patients who achieve Hb $\geq$ 11.0 g/dl<br>ESA-treated: % of patients who achieve mean Hb $\geq$ 10.0 g/dl<br>Part 2 (weeks 21–36):<br>Mean Hb at weeks 33–37   | Nov 2021        |
| <b>Vadadustat</b>                                     |                            |                  |  |                 |
| Phase 1, R, OL, AC, PG (NCT03992066)                  | DD-CKD (M-HD); n = 35      | DPO Epoetin alfa | 1. $AUC_{last}$ , $AUC_{\infty}$ , $C_{max}$ , $T_{max}$ , $t_{1/2}$ , CL/F, Vd/F for vadadustat and ESA<br>2. $T_{max}$ , $AUC_{last}$ , $AUC_{\infty}$ , $C_{max}$ for vadadustat metabolite(s)<br>3. Serum erythropoietin level for the ESA therapy group | Jul 2020        |
| Phase 2, R, OL, AC, PG (FO2RWARD-2; NCT03799627)      | DD-CKD (M-HD); n = 125     | Epoetin alfa     | Mean change from baseline in Hb at weeks 10–12   | Jul 2020        |

AC, active controlled;  $AUC_{\infty}$ , area under the concentration-time curve from 0 to infinity;  $AUC_{last}$ , area under the concentration-time curve from 0 to last quantifiable concentration; CKD, chronic kidney disease; CL/F, apparent clearance;  $C_{max}$ , peak plasma concentration; CV, cardiovascular; DB, double blind; DPO, darbepoetin alfa; DD, dialysis dependent; ESA, erythropoietin-stimulating agent; Fe, iron; Hb, hemoglobin; HD, hemodialysis; I-DD, incident dialysis (HD or PD); I-HD, incident HD; MACE, major adverse CV event; M-DD, maintenance/stable dialysis (HD or PD); M-HD, maintenance HD; NC, noncomparative; NDD, non-dialysis dependent; OL, open label; PBO, placebo; PC, PBO controlled; PD, peritoneal dialysis; PG, parallel group; R, randomized; rhEPO, recombinant human erythropoietin; SBP, systolic blood pressure;  $t_{1/2}$ , terminal half-life;  $T_{max}$ , time to  $C_{max}$ ; Vd/F, apparent volume of distribution.

maintenance (n = 3554) hemodialysis.<sup>99</sup> Noninferiority criteria, compared with ESAs, were also met by roxadustat in Chinese maintenance dialysis patients (n = 256) versus epoetin alfa,<sup>22</sup> in Japanese maintenance hemodialysis patients (n = 303) versus darbepoetin alfa,<sup>18</sup> and in a larger international, randomized, phase 3 study of incident dialysis patients (n = 1043) versus epoetin alfa (HIMALAYAS; preliminary data).<sup>96</sup> In addition, HIMALAYAS reported superiority of roxadustat over epoetin alfa with regard to mean Hb change from baseline; the study included epoetin alfa-naïve patients and patients with limited prior epoetin alfa use.<sup>96</sup> Preliminary data from 3 other randomized phase 3 studies of dialysis patients (PYRENEES [n = 836],<sup>90</sup> ROCKIES [n = 2133],<sup>97</sup> and SIERRAS [n = 741]<sup>98</sup>) also indicated that roxadustat was associated with greater improvements in mean Hb than ESA therapy in treating anemia, including in patients with elevated C-reactive protein.<sup>97</sup> Furthermore, reduced i.v. iron use was reported in the PYRENEES and ROCKIES trials,<sup>90,97</sup> while the SIERRAS study and a pooled analysis of the 3 trials reported reduced transfusion rates.<sup>98,122</sup>

Similar to NDD CKD patients, consistent decreases in serum hepcidin and ferritin levels and increases in total iron binding capacity and serum TF were observed in DD CKD patients in phase 2 and 3 trials, in line with stimulated erythropoiesis and iron utilization.<sup>13,16–18,22,80,100,102,107,115–121</sup>

### THERAPEUTIC BENEFITS

HIF-PHIs induce robust Hb response in patients with anemia of CKD. Because HIF transcription factors regulate a broad spectrum of hypoxia responses, HIF-PHIs are predicted to have clinical effects beyond the stimulation of endogenous EPO (Figure 2<sup>51</sup>). Validation of predicted non-EPO benefits still requires well-designed and properly controlled clinical trials. Specifically, it will be important to: (i) corroborate the predicted ferrokinetic properties of HIF-PHIs and determine their impact on i.v. iron supplementation needs; (ii) establish whether patients need to be iron replete and which iron parameters should be met before HIF-PHIs can be safely initiated; (iii) determine whether HIF-PHIs can be effectively and safely used in patients with inflammation; (iv) determine whether HIF-PHI therapy impacts cardiovascular risk and mortality; (v) determine whether HIF-PHI therapy impacts CKD progression; and (vi) determine which CKD subgroups are most likely to benefit from HIF-PHIs. Furthermore, a better understanding is needed of the differences between individual HIF-PHIs with regard to pharmacokinetics, therapeutic window, nonerythropoietic actions (e.g., cardiovascular, metabolic, and blood pressure effects), and adverse effects.

### Stimulation of endogenous EPO

When administered i.v., ESA therapy may lead to supra-physiological plasma EPO concentrations,<sup>123</sup> which are associated with increased cardiovascular risk and mortality in CKD patients.<sup>124</sup> Compared with ESA-treated dialysis patients, substantially lower peak serum EPO concentrations

were measured in patients treated with HIF-PHIs.<sup>88,114</sup> The impact of lower serum EPO concentrations with HIF-PHIs on cardiovascular outcome is not clear. Possible explanations for lower serum EPO levels in patients treated with HIF-PHIs include direct effects of HIF-PHIs on erythroid progenitors and bone marrow environment facilitating erythropoiesis, beneficial effects on iron utilization, and potential differences in the biochemical properties of recombinant versus endogenous EPO, such as differences in ligand receptor interaction and glycosylation patterns.

Although the kidney is the main source of EPO in adults under normal physiological conditions, the liver produces differentially glycosylated forms of EPO that contribute to the plasma EPO pool under hypoxic conditions, and can be biochemically differentiated from kidney-derived EPO.<sup>50,125</sup> In patients with CKD, biochemical analysis suggested that hepatic EPO production correlated inversely with declining estimated glomerular filtration rate.<sup>126</sup> In addition to renal EPO production, hepatic EPO production can be substantially stimulated by pharmacologic HIF-PHD inhibition in rodent models of renal anemia.<sup>49,53,71,127</sup> Although liver EPO production has not been specifically examined in current clinical trials, a single-dose phase 1 study demonstrated that FG-2216, a compound related to roxadustat, resulted in increased plasma EPO concentrations in anephric patients.<sup>128</sup> Whether higher doses of HIF-PHI will be needed for efficacious treatment of anemia in anephric patients is not clear and will have to be addressed in future studies. Of interest in this context is a novel HIF-PHI compound (TP0463518), which appears to specifically target hepatic EPO production.<sup>129</sup>

### Iron metabolism

As discussed by Agarwal<sup>130</sup> in this supplement, the potential benefits of HIF-PHIs include hepatic hepcidin suppression and upregulation of iron metabolism and transport genes, such as *DCYTB*, *DMT1*, and *TF* (Figure 2).<sup>53</sup> These HIF-PHI responses are predicted to provide improvements in iron mobilization and utilization.<sup>53</sup> Although HIF-PHI administration in clinical trials was consistently associated with decreased serum hepcidin levels and increased total iron binding capacity and/or serum TF, there is no direct evidence from iron absorption studies or direct measurement of intestinal iron metabolism gene expression in patients with CKD.

Dedicated studies are needed to establish the degree by which HIF-PHIs impact clinical iron management, especially in patients with inflammation. Because of general iron loading in many patients to avoid functional iron deficiency, the degree to which iron supplementation needs are lower in HIF-PHI-treated patients is difficult to quantify. Nevertheless, several studies have included patients who (i) did not receive iron supplementation during HIF-PHI treatment; (ii) were not iron replete at baseline (i.e., iron replete defined as ferritin >100 ng/ml and TF saturation >20%), but received oral iron supplementation; or (iii) were on hemodialysis and received oral or i.v. iron.<sup>13,22,23,105,107,108,115,121</sup>

In incident dialysis patients, roxadustat treatment without iron supplementation resulted in an initial Hb increase; however, Hb started to plateau at a lower Hb level after 7 weeks of the 12-week study period compared with iron-treatment groups.<sup>121</sup> Similar to ESAs, HIF-PHIs can produce a state of relative iron deficiency in which the sudden increase in bone marrow iron requirements surpasses enteral iron uptake and mobilization from internal stores, necessitating iron supplementation in patients with borderline iron stores.<sup>131,132</sup> In the same study, supplementation with either oral (50–195 mg/d elemental) or i.v. (50–62.5 mg/wk elemental) iron was equally effective in raising and maintaining Hb levels.<sup>121</sup> As oral iron is inferior to i.v. iron in ESA-treated dialysis patients,<sup>2</sup> this suggests that HIF-PHIs may have beneficial effects on enteral iron uptake and/or utilization. This notion is further supported by data from a phase 3 study in Chinese patients on hemodialysis who were successfully treated with roxadustat in conjunction with oral iron only,<sup>22</sup> and preliminary data from the roxadustat PYRENEES and ROCKIES trials<sup>90,97</sup> and a phase 3 daprodustat study in Japanese hemodialysis patients,<sup>14</sup> which reported i.v. iron-sparing effects in comparison with ESA therapy. In NDD CKD patients treated with roxadustat who were permitted oral but not i.v. iron, mean Hb increases and response rates with roxadustat were similar between patients who were iron replete and not iron replete at baseline.<sup>108</sup> However, this study did not control for iron supplementation, and patients were not adequately stratified.

### Patients with inflammation

As discussed by Raichoudhury and Spinowitz<sup>133</sup> in this issue of the supplement, inflammation suppresses erythropoiesis via cytokine-mediated effects on bone marrow, iron metabolism (elevated serum hepcidin levels), EPO responsiveness and synthesis, and other mechanisms.<sup>55</sup> Preclinical data indicate that HIF-PHIs have the potential to correct Hb levels under inflammatory conditions. In a rodent model of inflammatory anemia, increases in hematocrit and renal EPO expression, and decreases in liver hepcidin and renal monocyte chemoattractant protein 1 transcription, have been demonstrated in response to molidustat administration.<sup>127</sup> Comparable erythropoietic effects were seen with JNJ-42905343 (HIF-PHI in preclinical development) and roxadustat in experimental inflammation.<sup>53,134</sup> In addition to proerythropoietic effects, HIF-PHIs have been shown to have anti-inflammatory effects in several disease models, such as acute ischemic injury and sepsis. The underlying mechanisms are complex, highly context dependent, and likely to involve interactions between the HIF pathway and proinflammatory nuclear factor- $\kappa$ B signaling, direct and/or indirect effects of cytokine production, and modulation of innate and adaptive immune responses.<sup>135,136</sup>

In a single-arm study, 29% of ESA-hypo-responsive patients responded to daprodustat and increased or maintained Hb levels over 16 weeks.<sup>137</sup> However, the small study population limited any conclusions as to whether daprodustat was efficacious in this patient subgroup.<sup>137</sup> Nevertheless, roxadustat

and vadadustat appear to be efficacious in patients with elevated baseline C-reactive protein, and dose increases were not required to reach Hb target levels.<sup>18,22,92,97,108,119,121,138</sup> Further studies are needed to confirm the efficacy, dose requirements, and safety of HIF-PHIs in patients with underlying inflammation over a wider range of C-reactive protein levels and/or ESA hyporesponsiveness.

### SAFETY

Because HIF-1 and HIF-2 control multiple biologic processes, systemic HIF-PHD inhibition may potentially produce adverse on-target effects. These effects will most likely depend on the dosing and pharmacokinetics of the HIF-PHI agent. However, because regulation of EPO expression is highly sensitive to hypoxia compared with other HIF targets, such as VEGF,<sup>68,139</sup> HIF-PHIs may achieve desirable proerythropoietic effects at doses that do not elicit a broader spectrum of HIF responses in CKD patients, including stimulation of VEGF-dependent pathways.<sup>140</sup>

To date, HIF-PHIs have been generally well tolerated, and major signals of serious risk have not been reported in healthy volunteers<sup>69,70,73</sup> or in clinical trials (Table 5<sup>141,142</sup>). Serious adverse events (AEs), reported in phase 3 studies, have not been considered to be drug related and fell within the range of expected AE frequencies in CKD patients. However, the Japanese Pharmaceutical and Medical Devices Agency prescribing information includes a safety warning regarding the potential risk for thromboembolism, cerebral and myocardial infarction, pulmonary embolism, and deep vein and vascular access thrombosis with HIF-PHIs.<sup>141</sup> A higher incidence of thromboembolic events (11.3% vs. 3.9%) was reported with roxadustat versus darbepoetin alfa in the safety analysis of pooled phase 3 trials in hemodialysis patients.<sup>141</sup>

### Cardiovascular safety

Patients with CKD are at increased risk for cardiovascular events (e.g., myocardial infarction and stroke).<sup>143,144</sup> Although preclinical data have suggested that short-term systemic HIF activation provides protection from ischemic injury and may be beneficial in several renal and cardiovascular disease models,<sup>11,145</sup> rigorous cardiovascular outcome analysis is needed to determine whether long-term treatment of patients with CKD anemia is safe.

Preliminary data from 3 pooled phase 3 studies with roxadustat in dialysis patients (HIMALAYAS, ROCKIES, and SIERRAS trials; including both maintenance and incident dialysis patients) reported no increase in the risk for all-cause mortality and MACE (i.e., death, myocardial infarction, or stroke) for roxadustat compared with epoetin alfa, whereas the risk of MACE+ (i.e., MACE plus heart failure or unstable angina, requiring hospitalization) was significantly reduced (MACE+ hazard ratio [HR] 0.84; 95% confidence interval [CI], 0.73–0.97;  $P = 0.02$ ).<sup>122</sup> In the analysis of incident dialysis patients, both the risks of MACE and MACE+ were significantly reduced with roxadustat versus epoetin alfa (MACE HR, 0.70 [95% CI, 0.51–0.97] [ $P = 0.03$ ]; and

**Table 5 | Overview of SAEs and most common AEs reported in phase 3 clinical trials of hypoxia-inducible factor–prolyl hydroxylase inhibitors in patients with anemia and CKD**

| Variable               | NDD-CKD patients   | DD-CKD patients   |
|------------------------|--|---|
| <b>SAEs</b>            |  |   |
| Daprodustat            | <ul style="list-style-type: none"> <li>Data not available</li> </ul>   | <ul style="list-style-type: none"> <li>Severe shunt occlusion in 2 patients, intraocular lens dislocation in 1 patient<sup>13</sup></li> <li>Incidence of SAEs in Japanese HD patients was 15% vs. 27% with DPO; similar incidences of all SAEs for both groups, including shunt stenosis (3% vs. 4% with DPO) and shunt occlusion (&lt;1% vs. 2% with DPO)<sup>14</sup></li> </ul>   |
| Enarodustat            | <ul style="list-style-type: none"> <li>No difference in incidence of CV and hypertension-related events, or renal function parameters vs. DPO<sup>78</sup></li> </ul>  | <ul style="list-style-type: none"> <li>Incidence of SAEs was 14.9% vs. 14.0% with DPO<sup>77</sup></li> </ul>   |
| Roxadustat             | <ul style="list-style-type: none"> <li>Incidence of SAEs in Chinese patients is consistent with those observed in CKD patients (8.9% vs. 11.7% with PBO; 1 patient with serious hyperkalemia and 2 patients with serious metabolic acidosis)<sup>23</sup></li> <li>Incidence of SAEs<sup>a</sup> in Japanese patients was 11.1% in all patients (2.0% drug related; 6.1% leading to treatment discontinuation)<sup>88</sup></li> <li>OLYMPUS trial: incidence of all-cause mortality was 20.5% vs. 17.8% with PBO, and of SAEs was 57.4% vs. 54.4% with PBO<sup>a</sup></li> </ul> | <ul style="list-style-type: none"> <li>Incidence of SAEs in Chinese patients was 14.2% vs. 10% with epoetin alfa; most frequent SAE was vascular access complication (2.9% vs. 3.0% with epoetin alfa)<sup>22</sup></li> <li>Increased incidence of serious thromboembolic events based on PMDA safety data review of pooled Japanese phase 3 trials (8.2% vs. 2.6% for DPO)<sup>141</sup></li> <li>Incidence of SAEs in Japanese stable HD patients was 20.7% vs. 14.5% with DPO (drug related, 3.3% vs. 3.9%; leading to treatment discontinuation, 8.7% vs. 5.3%)<sup>18</sup></li> <li>SAEs reported in 29.3% of EPO-naïve and 28.2% of EPO-converted incident HD patients from Japan<sup>16</sup></li> <li>Incidence of SAEs in Japanese PD patients was 23.1% in ESA-naïve and 11.6% in ESA-converted patients; most common SAE was peritonitis (3.6% overall)<sup>17</sup></li> <li>PYRENEES trial: incidence of all-cause mortality was 18.8% vs. 14.1% with ESA, and of SAEs was 50.7% vs. 45.0% with ESA<sup>b</sup></li> <li>ROCKIES trial: incidence of all-cause mortality was 23.6% vs. 21.9% with epoetin alfa, and of SAEs was 57.6% vs. 57.6% with epoetin alfa<sup>c</sup></li> </ul> |
| Vadadustat             | <ul style="list-style-type: none"> <li>Incidence of SAEs was 13.9% vs. 14.4% with DPO<sup>19</sup></li> <li>PRO2TECT trial: incidence of SAEs was 65.3% vs. 64.5% with DPO in Correction study and 58.5% vs. 56.6% with DPO in Conversion study<sup>113</sup></li> </ul>   | <ul style="list-style-type: none"> <li>Incidence of SAEs was 13.0% vs. 10.6% with DPO<sup>20</sup></li> <li>INNO2VATE trial: incidence of SAEs was 49.7% vs. 56.5% with DPO in I-DD-CKD and 55.0% vs. 58.3% with DPO in M-DD-CKD<sup>142</sup></li> </ul>   |
| <b>Most common AEs</b> |  |   |
| Daprodustat            | <ul style="list-style-type: none"> <li>Nasopharyngitis (33% vs. 37% with CERA), constipation (7% vs. 12% with CERA), no difference in prespecified ocular, CV, and cancer-related AEs<sup>15</sup></li> </ul>  | <ul style="list-style-type: none"> <li>Similar incidence between newly started and established HD patients, most commonly reported were nasopharyngitis, infected dermal cysts, mild to moderate shunt stenosis<sup>13</sup></li> <li>In Japanese HD patients, higher incidence of diarrhea (15% vs. 9% with DPO) and contusion (13% vs. 8% with DPO), lower incidence of nasopharyngitis (42% vs. 54% with DPO) and pain in extremity (&lt;1% vs. 7% with DPO); incidence of hyperkalemia was 3% vs. 1% with DPO, but no clinically relevant change in potassium from baseline in either group; similar incidence of adverse ocular events with DAPRO vs. DPO<sup>14</sup></li> </ul>  |
| Enarodustat            | <ul style="list-style-type: none"> <li>No difference in incidence of CV events and hypertension-related events or in renal function parameters vs. DPO<sup>78</sup></li> </ul>   | <ul style="list-style-type: none"> <li>Incidence of any AE was 87.4% vs. 83.7% with DPO<sup>77</sup></li> </ul>   |
| Molidustat             | <ul style="list-style-type: none"> <li>ESA-naïve: AE incidence was 84.1% vs. 91.1% with DPO; nasopharyngitis (20.7% vs. 25.3% with DPO), worsening CKD (13.4% vs. 6.3% with DPO)<sup>86</sup></li> <li>ESA-converted: AE incidence was 87.8% vs. 89% with DPO; nasopharyngitis (28.3% vs. 30.5% with DPO), worsening CKD (12.2% vs. 7.3% with DPO)<sup>87</sup></li> </ul>   | <ul style="list-style-type: none"> <li>Data not available</li> </ul>  |

(Continued on following page)

Table 5 | (Continued)

| Variable   | NDD-CKD patients  | DD-CKD patients  |
|------------|---|--|
| Roxadustat | <ul style="list-style-type: none"> <li>Hyperkalemia (15.8% vs. 7.8% with PBO), metabolic acidosis (11.9% vs. 2.0% with PBO), hypertension (5.9% vs. 3.9% with PBO), peripheral edema (6.9% vs. 5.9% for PBO) in Chinese patients<sup>23</sup></li> <li>Most frequent (<math>\geq 5\%</math>) AEs<sup>d</sup> in Japanese patients were nasopharyngitis (20.2%), hyperkalemia (5.1%), and hypertension (6.1%)<sup>88</sup></li> <li>ALPS trial: common AEs were ESRD, hypertension, peripheral edema, and decreased GFR<sup>90</sup></li> <li>OLYMPUS trial: most common AEs were UTI (11.0% vs. 6.8% with PBO), hypertension (10.7% vs. 8.5% with PBO), peripheral edema (10.4% vs. 7.7% with PBO), and diarrhea (10.0% vs. 8.5% with PBO)<sup>a</sup></li> </ul> | <ul style="list-style-type: none"> <li>Increased frequency of upper respiratory infection compared with epoetin alfa (18.1% vs. 11.0%), and hyperkalemia (7.4% vs. 1.0%) in Chinese patients<sup>22</sup></li> <li>In Japanese HD patients, common (<math>\geq 10\%</math>) AEs were nasopharyngitis, (20.0%) and contact dermatitis (13.3%) in EPO-naïve patients, and nasopharyngitis (52.8%), diarrhea (11.0%), and vomiting (10.4%) in ESA-converted patients<sup>16</sup></li> <li>Nasopharyngitis (34.7% vs. 26.3% with DPO), new or worsening retinal hemorrhage (32.4% vs. 36.6% with DPO), shunt stenosis (7.3% vs. 8.6% with DPO), GI disorders (28.0% vs. 18.4% with DPO) in Japanese HD patients<sup>18</sup></li> <li>Higher incidence of AEs in Japanese ESA-converted vs. ESA-naïve PD patients, including nasopharyngitis, catheter site infection, and GI disorders; also reported back pain<sup>17</sup></li> <li>PYRENEES trial: common AEs were hypertension, AV fistula thrombosis, headache, and diarrhea<sup>90</sup></li> <li>ROCKIES trial: most common AE was diarrhea (10.9% vs. 9.6% with epoetin alfa)<sup>c</sup></li> </ul> |
| Vadadustat | <ul style="list-style-type: none"> <li>Nasopharyngitis (14.6% vs. 12.4% with DPO), diarrhea (10.6% vs. 3.3% with DPO), and constipation (5.3% vs. 3.9% with DPO)<sup>19</sup></li> <li>PRO2TECT trial: most common AEs were ESRD (34.7% vs. 35.2% with DPO), hypertension (17.7% vs. 22.1% with DPO), hyperkalemia (12.3% vs. 15.6% with DPO) in the Correction study, and ESRD (27.5% vs. 28.4% with DPO), hypertension (14.4% vs. 14.8% with DPO), urinary tract infection (12.2% vs. 14.5% with DPO) in the Conversion study<sup>113</sup></li> </ul>  | <ul style="list-style-type: none"> <li>Nasopharyngitis (19.8% vs. 28.6% with DPO), diarrhea (10.5% vs. 9.9% with DPO), and shunt stenosis (8.0% vs. 12.4% with DPO)<sup>20</sup></li> <li>INNO2VATE trial: most common AEs were hypertension (16.2% vs. 12.9% with DPO) and diarrhea (10.1% vs. 9.7% with DPO) in I-DD-CKD, and diarrhea (13.0% vs. 10.1% with DPO), pneumonia (11.0% vs. 9.7% with DPO), hypertension (10.6% vs. 13.8% with DPO), and hyperkalemia (9.0% vs. 10.8% with DPO) in M-DD-CKD<sup>142</sup></li> </ul>   |

AE, adverse event; AV, arteriovenous; CKD, chronic kidney disease; CV, cardiovascular; DD, dialysis-dependent; DPO, darbepoetin alfa; EPO, erythropoietin; ESA, erythropoietin-stimulating agent; ESRD, end-stage renal disease; GFR, glomerular filtration rate; GI, gastrointestinal; HD, hemodialysis; I-DD-CKD, incident DD-CKD; M-DD-CKD, maintenance DD CKD; NDD, non-dialysis-dependent; PBO, placebo; PD, peritoneal dialysis; PMDA, Japanese Pharmaceutical and Medical Device Agency; SAE, serious AE; UTI, urinary tract infection.

<sup>a</sup>Study results available from <https://clinicaltrials.gov/ct2/show/NCT02174627>.

<sup>b</sup>Study results available from <https://clinicaltrials.gov/ct2/show/NCT02278341>.

<sup>c</sup>Study results available from <https://clinicaltrials.gov/ct2/show/NCT02174731>.

<sup>d</sup>Severity of treatment-emergent AE was not specified.

MACE+ HR, 0.66 [95% CI, 0.50–0.89] [ $P = 0.005$ ],<sup>122</sup> suggesting an improvement in cardiovascular safety compared with the current standard of care. However, safety data from the smaller PYRENEES trial (in maintenance DD CKD patients only) were not included in this pooled analysis (see Table 5 for AE rates). The INNO2VATE trial, a large global study of vadadustat in dialysis patients, reported noninferiority compared with darbepoetin alfa with regard to MACE and all-cause mortality.<sup>99,142</sup> Preliminary cardiovascular safety data for NDD CKD patients have been reported for both roxadustat and vadadustat. In the pooled analysis of OLYMPUS, ALPS, and ANDES, the risks of MACE and MACE+ were not significantly different between the roxadustat and placebo groups.<sup>122</sup> In the global PRO2TECT study, which used a different trial design and compared cardiovascular outcomes with vadadustat versus darbepoetin alfa in patients with NDD CKD, vadadustat did not meet the primary safety MACE end point for noninferiority (MACE HR 1.14 [95% CI, 0.99–1.32]; all-cause mortality HR 0.99 [95% CI, 0.77–1.27]).<sup>94,113</sup> This increase in the HR for MACE

appeared to be largely driven by cardiovascular events in the non-US study population (MACE HR in the US population, 1.01 [95% CI, 0.83–1.23] vs. MACE HR in non-US population, 1.29 [95% CI, 1.03–1.60]).<sup>94,113</sup> Additional subgroup analysis is needed to understand the differences in cardiovascular safety outcomes between US and non-US populations and to identify the patient groups with the greatest risk of MACE.

Nonerythropoietic actions with potential impact on cardiovascular outcomes have been consistently reported in clinical studies of roxadustat and daprodustat, including reductions in total serum cholesterol, low-density and high-density lipoprotein cholesterol, and triglycerides.<sup>13,22,23,116</sup> These lipid-lowering effects can be explained by HIF-dependent increases in lipoprotein uptake and reductions in cholesterol synthesis via enhanced degradation of 3-hydroxy-3-methyl-glutaryl-CoA reductase.<sup>146,147</sup>

HIF-PHIs do not appear to cause QT interval prolongation, even at supratherapeutic doses,<sup>148</sup> or changes in echocardiographic parameters.<sup>101,115</sup> In general, HIF-PHI

treatment was not associated with significant changes in systolic or diastolic blood pressure.<sup>22,80,103,111</sup> However, almost twice as many daprodustat-treated patients had an increase in antihypertensive medications, although the mean increase in systolic blood pressure was lower with daprodustat in a 24-week hemodialysis study compared with control.<sup>115</sup>

### Renal safety

The effects of HIF-PHIs on CKD progression are unclear, and peer-reviewed data are not yet available. However, preliminary data from the MolIdustat once daily improves renal Anaemia By Inducing erythropoietin (MIYABI) Haemodialysis-Correction (HD-C) and Haemodialysis-Maintenance (HD-M) trials (n = 325) in NDD CKD patients with previously untreated or ESA-treated anemia indicated that worsening of CKD occurred more frequently with molidustat (13.4% and 12.2%, respectively) than darbepoetin alfa (6.3% and 7.3%, respectively).<sup>86,87</sup> In contrast, a preliminary pooled safety analysis of roxadustat-treated NDD CKD patients (n = 2438) suggested beneficial effects on glomerular filtration rate with roxadustat (1-year decline in estimated glomerular filtration rate of -2.8 vs. -4.4 ml/min with placebo).<sup>149</sup>

Hyperkalemia was reported more frequently with roxadustat in Chinese phase 3 studies in both NDD CKD and DD CKD patients.<sup>22,23</sup> Although the underlying mechanisms are unclear, metabolic acidosis was reported in 12% of roxadustat-treated NDD CKD patients.<sup>23</sup> Hyperkalemia was also observed in phase 2 trials in patients treated with other HIF-PHIs.<sup>106,111,115</sup>

### Other safety considerations

Despite concerns regarding proangiogenic effects of HIF-PHIs in patients with vascular retinopathy,<sup>150</sup> there was no increase in the incidences of retinal hemorrhage, macular edema, or changes in intraocular pressure or visual acuity in clinical studies with roxadustat or daprodustat.<sup>14,18,101,115</sup> In Japanese hemodialysis patients, ophthalmologic evaluation reported new or worsening retinal hemorrhage in 32.4% of roxadustat-treated versus 36.6% of darbepoetin alfa-treated patients overall, and in 19.1% of roxadustat-treated versus 25.0% of darbepoetin alfa-treated patients without prior retinal lesions.<sup>18</sup>

Several concerns regarding the long-term safety of HIF-PHIs have remained unanswered, and extended clinical studies and/or postmarketing investigations will be needed. These concerns are based on observations made in genetically modified animals with HIF-activating mutations, physiological and pathologic responses to high altitude,<sup>151</sup> and clinical manifestations in patients with genetic mutations in the HIF pathway, such as patients with Chuvash polycythemia or certain neuroendocrine tumors.<sup>152</sup>

There are theoretical concerns that systemic HIF activation may be pro-oncogenic, promote tumor growth, or facilitate metastasis given that HIF activation is evident in many cancers, and that growing tumors experience hypoxia and co-opt the HIF pathway for metabolic adaptation and angiogenesis.<sup>153</sup> To date, animal studies have shown no

evidence that prolonged exposure to HIF-PHIs is pro-oncogenic.<sup>140,154,155</sup> Although preliminary data from phase 3 roxadustat studies indicated that the rates of neoplasm-related AEs were not increased compared with placebo or epoetin alfa in patients with NDD CKD or DD CKD,<sup>156</sup> long-term observations in humans are needed to rule out any possible pro-oncogenic properties of HIF-PHIs. Given the multiple theoretical safety concerns and the exclusion of patients with a history of cancer (<2–5 years) from clinical trials, the use of HIF-PHIs in patients with cancer should not be recommended, as safety data are not available.

Other concerns include the potential risk for pulmonary arterial hypertension, as HIF activation increases vascular tone in pulmonary arteries<sup>157–159</sup>; thromboembolic events, which have been observed in patients with Chuvash polycythemia<sup>160,161</sup>; promotion of renal cyst growth<sup>162</sup>; AEs on glucose and liver metabolism<sup>51</sup>; profibrogenic effects in kidney and other organs<sup>163</sup>; and AEs on vascular calcifications and fibroblast growth factor 23 levels.<sup>164,165</sup> There are also concerns regarding HIF-PHI use in patients with autoimmune diseases, viral hepatitis, and other infections.<sup>51</sup>

### OTHER INDICATIONS

In addition to the management of anemia of CKD, clinical studies are investigating the efficacy and safety of HIF-PHIs in other diseases, including anemia associated with myelodysplastic syndrome (NCT03263091 and NCT03303066), chemotherapy-induced anemia (NCT04076943), wound healing (NCT01831804), diabetic foot ulcers (NCT03153007), sarcopenia of aging (NCT03371134), peripheral vascular disease (NCT02135848), and inflammatory bowel disease (NCT02914262).

### CONCLUSIONS

The efficacy of HIF-PHIs for the treatment of anemia of CKD has been well established in clinical trials, with 4 compounds being under license for marketing in Asia. Going forward, several questions and concerns regarding the use of HIF-PHIs in clinical practice need to be addressed. Aside from establishing long-term safety in extended trials and postmarketing analysis, evidence-based guidance will be required as to the laboratory and clinical parameter criteria for the safe use of HIF-PHI therapy. It will be important to differentiate between CKD patients who will clearly benefit from HIF-PHIs and those in whom treatment should not be started. This will require rigorous comparisons to current standard of care in both CKD patients on and not on dialysis.

### DISCLOSURE

VHH has received consulting fees from Akebia Therapeutics, AstraZeneca, FibroGen, and Rockwell Medical.

### ACKNOWLEDGEMENTS

This article is published as part of a supplement supported by AstraZeneca. Medical writing assistance was provided by Sarah Greig, PhD (Auckland, New Zealand) and Meri Pozo, PhD, CMPP (New York, NY, USA), of inScience Communications (and funded by AstraZeneca).

Roxadustat is being developed for clinical use by an alliance of FibroGen, Astellas, and AstraZeneca.

VHH apologizes to those colleagues whose original publications could not be cited because of space limitations. VHH is supported by the Krick-Brooks Chair in Nephrology at Vanderbilt University. More information about research performed in the Haase laboratory can be found at <https://www.haaselab.org>.

#### AUTHOR CONTRIBUTIONS

VHH meets the International Committee of Medical Journal Editors criteria for authorship for this article and takes responsibility for the integrity of the work as a whole. VHH wrote the article with the assistance of medical writers from inScience Communications and is fully accountable for all aspects of the work.

#### REFERENCES

- Kidney Disease: Improving Global Outcomes. Notice. *Kidney Int Suppl.* 2013;3:1–150.
- Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. *Nat Rev Nephrol.* 2010;6:699–710.
- Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med.* 1998;339:584–590.
- Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. *Clin J Am Soc Nephrol.* 2009;4:33–38.
- Parfrey PS, Lauve M, Latremouille-Viau D, et al. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. *Clin J Am Soc Nephrol.* 2009;4:755–762.
- Finkelstein FO, Finkelstein SH. The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era. *Adv Chronic Kidney Dis.* 2019;26:250–252.
- Singh AK, Szczec L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med.* 2006;355:2085–2098.
- Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med.* 2006;355:2071–2084.
- Pfeffer MA, Burdman EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med.* 2009;361:2019–2032.
- Semenza GL. Oxygen sensing, homeostasis, and disease. *N Engl J Med.* 2011;365:537–547.
- Schodel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. *Nat Rev Nephrol.* 2019;15:641–659.
- Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. *Nat Chem Biol.* 2008;4:152–156.
- Tsubakihara Y, Akizawa T, Nangaku M, et al. A 24-week anemia correction study of daprodustat in Japanese dialysis patients. *Ther Apher Dial.* 2020;24:108–114.
- Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. *Clin J Am Soc Nephrol.* 2020;15:1155–1165.
- Kimura T, Nangaku M, Hamano T, et al. Efficacy and safety of daprodustat compared with epoetin beta pegol in Japanese non-dialysis patients with anemia of chronic kidney disease: a 52-week, open-label, randomized controlled phase 3 trial [late-breaking clinical trial]. ERA-EDTA 2019 Congress. 2019. Budapest, Hungary.
- Akizawa T, Ueno M, Shiga T, et al. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies. *Ther Apher Dial.* 2020;24:628–641.
- Akizawa T, Otsuka T, Reusch M, et al. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. *Ther Apher Dial.* 2020;24:115–125.
- Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. *J Am Soc Nephrol.* 2020;31:1628–1639.
- Nangaku M, Kondo K, Kokado Y, et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract SA-PO229]. *J Am Soc Nephrol.* 2019;30:823.
- Nangaku M, Kondo K, Ueta K, et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract TH-OR024]. *J Am Soc Nephrol.* 2019;30:6.
- Japan Tobacco Inc. JT receives manufacturing and marketing approval of Enaroy® tablets 2 mg·4 mg for the treatment of anemia associated with chronic kidney disease in Japan. Available at: [https://www.jt.com/media/news/2020/pdf/20200925\\_E1.pdf](https://www.jt.com/media/news/2020/pdf/20200925_E1.pdf). Accessed February 10, 2021.
- Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. *N Engl J Med.* 2019;381:1011–1022.
- Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. *N Engl J Med.* 2019;381:1001–1010.
- Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. *J Biol Chem.* 1977;252:5558–5564.
- Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. *Nature.* 1985;313:806–810.
- Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. *Proc Natl Acad Sci U S A.* 1985;82:7580–7584.
- Goldberg MA, Glass GA, Cunningham JM, et al. The regulated expression of erythropoietin by two human hepatoma cell lines. *Proc Natl Acad Sci U S A.* 1987;84:7972–7976.
- Semenza GL, Neufeldt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. *Proc Natl Acad Sci U S A.* 1991;88:5680–5684.
- Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol.* 1992;12:5447–5454.
- Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. *J Biol Chem.* 1995;270:1230–1237.
- Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension. *Proc Natl Acad Sci U S A.* 1995;92:5510–5514.
- Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci U S A.* 1993;90:4304–4308.
- Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. *Proc Natl Acad Sci U S A.* 1993;90:2423–2427.
- Firth JD, Ebert BL, Pugh CW, et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. *Proc Natl Acad Sci U S A.* 1994;91:6496–6500.
- Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. *J Biol Chem.* 1995;270:13333–13340.
- Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF- $\alpha$  to the von Hippel-Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation. *Science.* 2001;292:468–472.
- Ivan M, Kondo K, Yang H, et al. HIF1 $\alpha$  targeted for VHL-mediated destruction by proline hydroxylation: implications for O<sub>2</sub> sensing. *Science.* 2001;292:464–468.
- Yu F, White SB, Zhao Q, et al. HIF-1 $\alpha$  binding to VHL is regulated by stimulus-sensitive proline hydroxylation. *Proc Natl Acad Sci U S A.* 2001;98:9630–9635.
- Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. *Proc Natl Acad Sci U S A.* 2002;99:13459–13464.
- Huang J, Zhao Q, Mooney SM, et al. Sequence determinants in hypoxia-inducible factor-1 $\alpha$  for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. *J Biol Chem.* 2002;277:39792–39800.
- Epstein AC, Gleadle JM, McNeill LA, et al. *C. elegans* EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell.* 2001;107:43–54.
- Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. *Science.* 2001;294:1337–1340.

43. Fandrey J, Schodel J, Eckardt KU, et al. Now a nobel gas: oxygen. *Pflugers Arch.* 2019;471:1343–1358.
44. McIntosh BE, Hogenesch JB, Bradfield CA. Mammalian Per-Arnt-Sim proteins in environmental adaptation. *Annu Rev Physiol.* 2010;72:625–645.
45. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell.* 2008;30:393–402.
46. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1 $\alpha$  and VHL to mediate repression of HIF-1 transcriptional activity. *Genes Dev.* 2001;15:2675–2686.
47. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. *Genes Dev.* 2002;16:1466–1471.
48. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. *J Clin Invest.* 2007;117:1068–1077.
49. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. *Blood.* 2010;116:3039–3048.
50. Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. *Nat Rev Nephrol.* 2015;11:394–410.
51. Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. *Adv Chronic Kidney Dis.* 2019;26:253–266.
52. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. *Trends Mol Med.* 2001;7:345–350.
53. Barrett TD, Palomino HL, Brondstetter TI, et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. *Br J Pharmacol.* 2015;172:4078–4088.
54. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science.* 2004;306:2090–2093.
55. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Blood.* 2019;133:40–50.
56. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. *Blood.* 2008;112:4292–4297.
57. van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. *Nat Rev Nephrol.* 2020;16:77–98.
58. Ganz T, Nemeth E. Hepcidin and iron homeostasis. *Biochim Biophys Acta.* 2012;1823:1434–1443.
59. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest.* 2002;110:1037–1044.
60. Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood.* 2006;108:3730–3735.
61. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. *Haematologica.* 2010;95:505–508.
62. Talbot NP, Lakhal S, Smith TG, et al. Regulation of hepcidin expression at high altitude. *Blood.* 2012;119:857–860.
63. Ganz T. Erythropoietic regulators of iron metabolism. *Free Radic Biol Med.* 2019;133:69–74.
64. Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. *Blood.* 2018;132:1473–1477.
65. Volke M, Gale DP, Maegdefrau U, et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. *PLoS One.* 2009;4:e7875.
66. Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. *J Clin Invest.* 2012;122:4635–4644.
67. Mastrogiannaki M, Matak P, Mathieu JR, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. *Haematologica.* 2012;97:827–834.
68. Yeh TL, Leissing TM, Abboud MI, et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. *Chem Sci.* 2017;8:7651–7668.
69. Hara K, Takahashi N, Wakamatsu A, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. *Drug Metab Pharmacokinet.* 2015;30:410–418.
70. Kansagra KA, Parmar D, Jani RH, et al. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. *Clin Pharmacokinet.* 2018;57:87–102.
71. Fukui K, Shinozaki Y, Kobayashi H, et al. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, stabilizes HIF- $\alpha$  protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. *Eur J Pharmacol.* 2019;859:172532.
72. Pai SM, Connaire J, Yamada H, et al. A mass balance study of (14) C-labeled JTZ-951 (enarodustat), a novel orally available erythropoiesis-stimulating agent, in patients with end-stage renal disease on hemodialysis. *Clin Pharmacol Drug Dev.* 2020;9:728–741.
73. Bottcher M, Lentini S, Arens ER, et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. *Br J Clin Pharmacol.* 2018;84:1557–1565.
74. Beck H, Jeske M, Thede K, et al. Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. *ChemMedChem.* 2018;13:988–1003.
75. Shibata T, Nomura Y, Takada A, et al. Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male Japanese subjects. *Clin Pharmacol Drug Dev.* 2019;8:304–313.
76. Chavan AB, Paulson SK, Burke L, et al. Effect of moderate hepatic impairment on pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) [abstract TH-PO369]. *J Am Soc Nephrol.* 2019;30:210.
77. Akizawa T, Maeda K, Miyazawa Y, et al. Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract TH-PO1186]. *J Am Soc Nephrol.* 2019;30:B4.
78. Akizawa T, Matsui A, Miyazawa Y, et al. Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD not requiring dialysis [abstract TH-PO1185]. *J Am Soc Nephrol.* 2019;30:B4.
79. Caltabiano S, Cizman B, Burns O, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. *Clin Kidney J.* 2019;12:693–701.
80. MaccDougall IC, Akizawa T, Berns JS, et al. Effects of molidustat in the treatment of anemia in CKD. *Clin J Am Soc Nephrol.* 2019;14:28–39.
81. Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. *Clin Pharmacol Drug Dev.* 2014;3:109–117.
82. Shibata T, Nomura Y, Takada A, et al. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects. *J Clin Pharm Ther.* 2018;43:633–639.
83. Eichner D, Van Wagoner RM, Brenner M, et al. Implementation of the prolyl hydroxylase inhibitor roxadustat (FG-4592) and its main metabolites into routine doping controls. *Drug Test Anal.* 2017;9:1768–1778.
84. Groenendaal-van de Meent D, den Adel M, van Dijk J, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, safety, and tolerability of roxadustat in healthy subjects. *Eur J Drug Metab Pharmacokinet.* 2018;43:685–692.
85. Caltabiano S, Mahar KM, Lister K, et al. The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. *Pharmacol Res Perspect.* 2018;6:e00327.
86. Akizawa T, Iekushi K, Matsuda Y, et al. P1866 to investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis-stimulating agents: Miyabi Nd-C. *Nephrol Dial Transplant.* 2020;35:iii2177.
87. Akizawa T, Iekushi K, Matsuda Y, et al. P1868 to investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis-stimulating agents: Miyabi Nd-M. *Nephrol Dial Transplant.* 2020;35:iii2179.
88. Akizawa T, Yamaguchi Y, Otsuka T, et al. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis. *Nephron.* 2020;144:372–382.

89. Akizawa T, Iwasaki M, Otsuka T, et al. A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract PO0269]. *J Am Soc Nephrol*. 2020;31:134.
90. Esposito C, Csiky B, Tataradze A, et al. Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract SA-PO225]. *J Am Soc Nephrol*. 2019;30:822.
91. Coyne DW, Roger SD, Shin SK, et al. ANDES: a phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract SA-PO228]. *J Am Soc Nephrol*. 2019;30:822.
92. Fishbane S, El-Shahawy MA, Pecoit-Filho R, et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract TH-OR023]. *J Am Soc Nephrol*. 2019;30:6.
93. Barratt J, Andre B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study. *Nephrol Dial Transplant*. 2020;35:iii101–iii102.
94. Chertow GM, PRO2TECT Author Group. Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract FR-OR54]. *J Am Soc Nephrol*. 2020;31:B2.
95. Akizawa T, Yamada H, Nobori K, et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. darbepoetin alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAs) [abstract PO2623]. *J Am Soc Nephrol*. 2020;31: B4.
96. Provenzano R, Evgeny S, Liubov E, et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract TH-OR021]. *J Am Soc Nephrol*. 2019;30:5.
97. Fishbane S, Pollock CA, El-Shahawy MA, et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract TH-OR022]. *J Am Soc Nephrol*. 2019;30:6.
98. Charytan C, Manllo-Karim R, Martin ER, et al. SIERRAS: a phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract SA-PO227]. *J Am Soc Nephrol*. 2019;30: 822.
99. Eckardt KU, INNO2VATE Author Group. Global phase 3 clinical trials of vadadustat vs darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract TH-OR01]. *J Am Soc Nephrol*. 2020;31:1.
100. Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. *Am J Kidney Dis*. 2016;67:861–871.
101. Holdstock L, Cizman B, Meadowcroft AM, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. *Clin Kidney J*. 2019;12:129–138.
102. Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. *J Am Soc Nephrol*. 2016;27:1234–1244.
103. Parmar DV, Kansagra KA, Patel JC, et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. *Am J Nephrol*. 2019;49:470–478.
104. Akizawa T, Nangaku M, Yamaguchi T, et al. A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. *Am J Nephrol*. 2019;49:165–174.
105. Akizawa T, Macdougall IC, Berns JS, et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. *Nephron*. 2019;143:243–254.
106. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. *Nephrol Dial Transplant*. 2015;30:1665–1673.
107. Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. *Nephrol Dial Transplant*. 2017;32:1373–1386.
108. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. *Clin J Am Soc Nephrol*. 2016;11:982–991.
109. Akizawa T, Iwasaki M, Otsuka T, et al. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. *Adv Ther*. 2019;36:1438–1454.
110. Martin ER, Smith MT, Maroni BJ, et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. *Am J Nephrol*. 2017;45:380–388.
111. Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. *Kidney Int*. 2016;90:1115–1122.
112. Nangaku M, Farag YMK, deGoma E, et al. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients [epub ahead of print]. *Nephrol Dial Transplant*. doi.org/10.1093/ndt/gfaa060. Accessed February 9, 2021.
113. Akebia Therapeutics. Akebia presents results from its PRO<sub>2</sub>TTECT global phase 3 program of vadadustat for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis during late-breaking session at American Society of Nephrology Kidney Week 2020 Reimagined. Available at: <https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-pro2tect-global-phase-3-program>. Accessed December 16, 2020.
114. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nat Genet*. 2014;46:678–684.
115. Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. *Clin Kidney J*. 2019;12:139–148.
116. Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. *Am J Nephrol*. 2017;45: 127–135.
117. Bailey CK, Caltabiano S, Cobitz AR, et al. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. *BMC Nephrol*. 2019;20:372.
118. Akizawa T, Nangaku M, Yamaguchi T, et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. *Nephron*. 2019;143:77–85.
119. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. *Am J Kidney Dis*. 2016;67:912–924.
120. Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. *Nephrol Dial Transplant*. 2019;34:90–99.
121. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. *J Am Soc Nephrol*. 2016;27:1225–1233.
122. Provenzano R, Fishbane S, Wei LJ, et al. Pooled efficacy and cardiovascular (CV) analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis [abstract FR-OR131]. *J Am Soc Nephrol*. 2019;30:B1.
123. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. *Clin J Am Soc Nephrol*. 2007;2:1274–1282.
124. Wagner M, Alam A, Zimmermann J, et al. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. *Clin J Am Soc Nephrol*. 2011;6:1573–1579.
125. Lonnberg M, Garle M, Lonnberg L, et al. Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis. *J Pharm Biomed Anal*. 2013;81–82:187–192.
126. de Seigneux S, Lundby AK, Berchtold L, et al. Increased synthesis of liver erythropoietin with CKD. *J Am Soc Nephrol*. 2016;27:2265–2269.
127. Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects. *PLoS One*. 2014;9:e111838.

128. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. *J Am Soc Nephrol.* 2010;21:2151–2156.
129. Shinfuku A, Shimazaki T, Fujiwara M, et al. Novel compound induces erythropoietin secretion through liver effects in chronic kidney disease patients and healthy volunteers. *Am J Nephrol.* 2018;48:157–164.
130. Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. *Kidney Int Suppl.* 2021;11:46–57.
131. Macdougall IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. *BMJ.* 1989;299:157–158.
132. Rutherford CJ, Schneider TJ, Dempsey H, et al. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. *Am J Med.* 1994;96:139–145.
133. Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. *Kidney Int Suppl.* 2021;11: 26–34.
134. Del Balzo U, Signore PE, Walkinshaw G, et al. Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment of anemia of chronic kidney disease. *J Pharmacol Exp Ther.* 2020;374:342–353.
135. Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. *Nat Rev Drug Discov.* 2014;13:852–869.
136. Taylor CT, Doherty G, Fallon PG, et al. Hypoxia-dependent regulation of inflammatory pathways in immune cells. *J Clin Invest.* 2016;126:3716–3724.
137. Cizman B, Sykes AP, Paul G, et al. An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects. *Kidney Int Rep.* 2018;3:841–850.
138. Haase VH, Khawaja Z, Chan J, et al. Vadadustat maintains hemoglobin (Hb) levels in dialysis-dependent chronic kidney disease (DD-CKD) patients independent of systemic inflammation or prior dose of erythropoiesis-stimulating agent (ESA) [abstract TH-PO960]. *J Am Soc Nephrol.* 2016;27:318A.
139. Sandner P, Gess B, Wolf K, et al. Divergent regulation of vascular endothelial growth factor and of erythropoietin gene expression in vivo. *Pflügers Arch.* 1996;431:905–912.
140. Seeley TW, Sternlicht MD, Klaus SJ, et al. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. *Hypoxia.* 2017;5:1–9.
141. PMDA. Japanese Pharmaceutical and Medical Devices Agency report on roxadustat. Available at: <https://www.pmda.go.jp/files/000234811.pdf>. Accessed July 22, 2020.
142. Akebia Therapeutics. Akebia presents results from its INNO2VATE global phase 3 program; demonstrated efficacy and cardiovascular safety of vadadustat for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Available at: <https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-inno2-vate-global-phase-3-program>. Accessed December 16, 2020.
143. Cozzolino M, Mangano M, Stucchi A, et al. Cardiovascular disease in dialysis patients. *Nephrol Dial Transplant.* 2018;33:iii28–iii34.
144. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet.* 2013;382:339–352.
145. Kapitsinou PP, Haase VH. Molecular mechanisms of ischemic preconditioning in the kidney. *Am J Physiol Renal Physiol.* 2015;309: F821–F834.
146. Hwang S, Nguyen AD, Jo Y, et al. Hypoxia-inducible factor 1 $\alpha$  activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. *J Biol Chem.* 2017;292:9382–9393.
147. Shen GM, Zhao YZ, Chen MT, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. *Biochem J.* 2012;441:675–683.
148. Caltabiano S, Collins J, Serbest G, et al. A randomized, placebo- and positive-controlled, single-dose, crossover thorough QT/QTc study assessing the effect of daprodustat on cardiac repolarization in healthy subjects. *Clin Pharmacol Drug Dev.* 2017;6:627–640.
149. FibroGen. FibroGen announces positive phase 3 pooled roxadustat safety and efficacy results for treatment of anemia in chronic kidney disease. Available at: <http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-phase-3-pooled-roxadustat-safety-and->. Accessed December 16, 2020.
150. Lin M, Chen Y, Jin J, et al. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells. *Diabetologia.* 2011;54:1554–1566.
151. West JB, Schoene RB, Milledge JS. *High Altitude Medicine and Physiology.* 4th ed. London, England: Hodder Arnold; 2007.
152. Semenza GL. The genomics and genetics of oxygen homeostasis. *Annu Rev Genomics Hum Genet.* 2020;21:183–204.
153. Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. *J Clin Invest.* 2019;129:442–451.
154. Beck J, Henschel C, Chou J, et al. Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats. *Int J Toxicol.* 2017;36:427–439.
155. Adams DF, Watkins MS, Durette L, et al. Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor. *Toxicol Pathol.* 2020;48:362–378.
156. Coyne DW, Fishbane S, Pergola PE, et al. Roxadustat is not associated with an increased risk of neoplasm in patients with CKD and anemia [abstract TH-OR04]. *J Am Soc Nephrol.* 2020;31:1.
157. Cowburn AS, Crosby A, Macias D, et al. HIF2 $\alpha$ -arginase axis is essential for the development of pulmonary hypertension. *Proc Natl Acad Sci U S A.* 2016;113:8801–8806.
158. Kapitsinou PP, Rajendran G, Astleford L, et al. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. *Mol Cell Biol.* 2016;36:1584–1594.
159. Shimoda LA, Yun X, Sikka G. Revisiting the role of hypoxia-inducible factors in pulmonary hypertension. *Curr Opin Physiol.* 2019;7:33–40.
160. Kaneko M, Minematsu T, Yoshida M, et al. Compression-induced HIF-1 enhances thrombosis and PAI-1 expression in mouse skin. *Wound Repair Regen.* 2015;23:657–663.
161. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythemia. *Semin Thromb Hemost.* 2006;32:289–294.
162. Kraus A, Peters DJM, Klanke B, et al. HIF-1 $\alpha$  promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. *Kidney Int.* 2018;94:887–899.
163. Liu J, Wei Q, Guo C, et al. Hypoxia, HIF, and associated signaling networks in chronic kidney disease. *Int J Mol Sci.* 2017;18:950.
164. Moka S, Lariviere R, Lamalice L, et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. *Kidney Int.* 2016;90:598–609.
165. Flamme I, Ellinghaus P, Urrego D, et al. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. *PLoS One.* 2017;12:e0186979.